Search by individual drug
*The Area Prescribing Committee may accept shared care guidelines that have been produced by other organisations.
Drug or Device | Indications | Classification | APC Date or Other (n) = New (a) = Amendment |
---|---|---|---|
3C Patch | For treating diabetic foot ulcers | Do not prescribe/not yet classified | WY ICS APC November 2022 |
3,4-diaminopyridine | Lambert-Eaton myasthenic syndrome (LEMS) (commissioned by NHS England) | Red | |
5-Aminolaevulinic Acid gel (78mg/g) | For dermatology for treatment of actinic keratosis of mild to moderate severity (Olsen grade 1 and 2) and of field cancerization in adults – Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. | Red | WY ICS APC March 2023 (n) |
5-methoxypsoralen | PUVA treatment of psoriasis | Red | |
Abacavir | HIV infection (commissioned by NHS England) | Red | |
Abacavir/dolutegravir/lamivudine | HIV infection (commissioned by NHS England) | Red | |
Abacavir/lamivudine | HIV infection (commissioned by NHS England) | Red | |
Abatacept | All indications | Red | |
Abatacept subcutaneous or intravenous injection | For morphoea (localised scleroderma) in adults | Red | WY ICS APC Chair's action January 2022. |
Abemacicib | For treating hormone receptor-positive human epidermal growth factor receptor 2 (HER2) - negative locally advanced or metastatic breast cancer | Red | WY ICS APC April 2022 |
Abemaciclib | Treatment of cancer (commissioned by NHS England) | Red | 31st July 2019 (n) |
Abiraterone | For use in treatment of cancer (Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned - see specialist advice) | Red | WY ICS APC November 2022 (a) |
Abrocitinib | For treating moderate to severe atopic dermatitis NICE TA814 | Red | WY ICS APC November 2022 |
Acalabrutinib | For chronic lymphocytic leukaemia | Red | 28th July 2021 (n) |
Acamprosate | Maintain abstinence in alcohol-dependent patients | Acamprosate | March 2021 (a) |
Acarovac Plus s/c injection | For allergic diseases caused by house dust mite (unlicensed) | Red | WY ICS APC Nov 2023 |
Acetylcysteine (unlicensed preparations) | For idiopathic pulmonary fibrosis | Do not prescribe | WY ICS APC Nov 2023 (a) |
Acetylcysteine nebulised | For treating cystic fibrosis in adults and children | Do not prescribe | WY ICS APC Nov 2023 |
Acetylcysteine | COPD | Green | 31st July 2019 (n) |
Acitretin | Oral retinoid for psoriasis | Red | |
Aclidinium bromide powder inhaler | Chronic obstructive pulmonary disease (COPD) | Green | |
Actimorph | For the management of breakthrough pain in patients at risk of overdose (either intentional or unintentional), patients with dexterity and cognition issues or patients unable to tolerate other forms of morphine | Green Restricted | WY ICS APC November 2022 |
Actipatch® | Pain | Black not yet classified | |
Adalimumab | All indications | Red | |
Adaliumab injection | For moderate rheumatoid arthritis | Red | WY ICS APC 20th October 2021 (n) |
Afatinib | Treatment of cancer (commissioned by NHS England) | Red | |
Aflibercept | All indications | Red | |
Agalsidase alfa | Fabry's disease (commissioned by NHS England) | Red | |
Agalsidase beta | Fabry's disease (commissioned by NHS England) | Red | |
Agomelatine | For the treatment of depression in adults | Agomelatine | WY ICS APC Sept 2023 |
Albumin-bound paclitaxel | Treatment of cancer (commissioned by NHS England) | Red | |
Albutropin | Adult onset growth hormone deficiency (NHS England) | Red | |
Aldesleukin | Treatment of cancers (NHS England) | Red | |
Alectinib | Treatment of cancer (commissioned by NHS England) | Red | |
Alemtuzumab | All indications | Red | |
Alglucosidase alfa | Pompe disease (commissioned by NHS England) | Red | |
Alirocumab | For treating adults with high cholesterol levels in their blood NICE TA393 | Red | WY ICS APC November 2033 |
Aliskiren | For treating hypertension | Do not prescribe | WY ICS APC Sept 2023 |
Alitretinoin | Severe chronic hand eczema refractory to potent topical corticosteroids | Red | |
Alogliptin | Type 2 diabetes (T2DM) | Green | |
Alpelisib tablet in combination with fulvestrant | For HR positive HER2 negative breast cancer | Red | WY ICS APC 22nd June 2022 |
Alprostadil cream | Erectile Dysfunction | Green Specialist Initiation | 18th March 2020 (n) |
Alteplase | Thrombolytic | Red | |
Ambrisentan | Pulmonary arterial hypertension (commissioned by NHS England) | Red | |
Amiodarone | Treatment of Ventricular and Supraventricular Arrhythmias for Adult Patients | Amiodarone | WY ICS APC May 2023 |
Amifampridine | Lambert-Eaton myasthenic syndrome (LEMS) (NHS England) | Do not Prescribe | |
Amikacin | Treatment of bacterial infections in adult and paediatric patients | Red | WY ICS APC 24th May 2023 |
Amikacin inhalation | Cystic fibrosis (CF) | Red | |
Amikacin liposomal | Cystic fibrosis (CF) | Red | |
Amphotericin liposomal | Fungal infections | Red | |
Amisulpride | Atypical antipsychotic for schizophrenia | Green Specialist Initiation | |
Anagrelide | Essential thrombocythaemia | Red | |
Anakinra | All indications | Red | |
Anakinra SC injection | For Haemophagoncytic Lymphohistiocytosis (HLH) for adults and children in all ages | Red | WY ICS APC 22nd June 2022 |
Anastrozole | Breast Cancer - long term therapy | Green Specialist Initiation | |
Andexanet | For reversing anticoagulation from apixaban or rivaroxaban NICE TA697 | Red | WY ICS APC April 2022 |
Anidulafungin | IV antifungal agent | Red | |
Anoro Ellipta 55/22® | Chronic obstructive pulmonary disease (COPD) | Green | |
Antacid and Oxetacaine | For radiotherapy induced oesophagitis (ULM) | Red | WY ICS APC November 2022 |
Anti-epileptic drugs (AED) in children | See LTHT guidance for information | Green Specialist Initiation | |
Antihistamines for hay fever (OTC or prescription) | For treatment of mild to moderate hay fever | Black | 28th July 2021(a) |
Antihaemophilic factor/Von Willebrand factor complex | As per BCSH guidelines for specialised indications | Red | |
Antilymphocyte globulin | Aplastic anaemia organ transplant | Red | |
Antithrombin III | As per BCSH guidelines for specialised indications | Red | |
Antithymocyte immunoglobulin | Aplastic anaemia organ transplant | Red | |
Anti-retrovirals | HIV infection (commissioned by NHS England) | Red | |
Antox® | Anti-oxidant therapy for pancreatitis | Green Specialist Initiation | |
Apalutamide | For treating high-risk hormone-relapsed non-metastatic prostate cancer and for treating hormone-sensitive metastatic prostate cancer NICE TA740 & TA741 | Red | WY ICS APC April 2022 |
Apixaban | See DOACs | See DOACs | |
Apixaban | For the prevention of venous thrombo-embolism (VTE) in patients with multiple myeloma (ULM) | Red | WY ICS APC Nov 2023 |
Apomorphine | Parkinson's disease | Green Specialist Initiation | |
Apraclonidine | Short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery. On advice from ophthalmology only with clear instruction on duration of treatment and plan for follow up. | Specialist Initiation Restricted | WY ICS APC November 2022 |
Apremilast | According to NICE (TA433) for the treatment of active psoriatic arthritis & (TA419) for treating moderate to severe plaque psoriasis | Red | |
Apremilast | Paediatric indications | Red | |
Aprepitant | Nausea/vomiting with highly emetogenic chemotherapy | Red | |
Aragam® | All indications | Red | |
Aripiprazole (oral) | Schizophrenia | Green Specialist Initiation | 31st July 2019 (a) |
Aripiprazole injection | Schizophrenia | Red | 31st July 2019 (n) |
Arsenic trioxide | Treatment of cancer (commissioned by NHS England) | Red | |
Artemether with lumefantrine | For the treatment of acute uncomplicated Plasmodium falciparum malaria in-line with national guidance. | Red | WY ICS APC July 2023. |
Artesunate | Treatment of severe malaria | Red | 22nd January 2020 |
Asciminib | For treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors NICE TA813 | Red | wY ICS APC November 2022 |
Asenapine | Treatment of bipolar disorders | Red | WY ICS APC Jan 2024 |
Asfotase alfa | Hypophosphatasia | Red | |
Ataluren | Duchenne muscular dystrophy | Red | |
Atazanavir | HIV infection (commissioned by NHS England) | Red | |
Atazanavir/cobicistat | HIV infection (commissioned by NHS England) | Red | |
Atezolizumab | Treatment of cancer (commissioned by NHS England) | Red | |
Atezolizumab concentrate for solution for infusion | For adjuvant treatment following complete resection for adult patients with Stage II to IIIA non-small cell lung cancer whose tumours have PD-L 1 expression. | Red | WY ICS APC 22nd June 2022 |
Atovaquone | Treatment of mild to moderate Pneumocystis jirovecii pneumonia in patient’s intolerant of co-trimoxazole. Use for prophylaxis against pneumocystis pneumonia. Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice | Red | WY ICS APC March 2023 (n) |
Atropine Eye Drops | For delaying the progress of myopia in children | Red | WY ICS APC March 2023 (n) |
Atropine Eye drops | For treatment of hypersalivation (unlicensed use) | Green | WY ICS APC March 2023 (n) |
Autologous chrondocyte implantation | Articular cartilage defect | Red | |
Autologous serum eye drops | Dry eye | Red | |
Atomoxetine | For attention deficit hyperactivity disorder (ADHD) in school-age children, adolescents and adults | Amber | Currently under RMOC consultation and will update accordingly - July 2021 |
Avacopan | Treatment of adult patients with severe, active granulomatosis with polyangiitis NICE TA825 | Red | WY ICS APC November 2022 |
Avanafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black | |
Avanafil | Erectile dysfunction in adult males | Green | |
Avastin | For neovascular glaucoma and neovascularization of the retina | Red | |
Avatrombopag | For treating severe thrombocytopenia in adults with chronicliver disease having planned invasive procedures | Red | WY ICS APC April 2022 |
Avelumab | Treatment of cancer (commissioned by NHS England) | Red | |
Avelumab solution for infusion | For untreated metastic Merkel cell carcinoma | Red | WY ICS APC Chair's action January 2022. |
Axicabtagene ciloleucel | Treatment of cancer (commissioned by NHS England) | Red | |
Axitinib | Treatment of cancer (commissioned by NHS England) | Red | |
Azacitidine | Treatment of cancer (commissioned by NHS England) | Red | |
Azathioprine 75mg and 100mg tablets (new strengths) | Indicated in immunosuppressive regimens. Concerns these new strengths could lead to overdose as they have bnot been available in the UK before. | Do not Prescribe/Not yet Classified | WY ICS APC Jan 2024 |
Azathioprine | Transplant immunosuppression | Amber Search for azathioprine/a> | Currently under RMOC consultation and will update accordingly - July 2021 |
Azathioprine | Paediatric Inflammatory Bowel Disease (IBD) / Rheumatology | Amber | Currently under RMOC consultation and will update accordingly - July 2021 |
Azathioprine and mercaptopurine | For patients within adult sevices (non-transplant indications). | Amber | W ICS APC July 2023. |
Azithromycin | Long term treatment bronchiectasis & COPD | Green Specialist Initiation | |
Azithromycin eye drops | Purulent bacterial conjunctivitis | Red | 29th July 2020 (n) |
Azithromycin 15mg/g (1.5%) eye drops | For the treatment of blepharitis in adults and children | Specialist Initiation | WY ICS APC November 2022 |
Aztreonam lysine | Cystic fibrosis (CF) Patients | Red | 20th September 2019 (a) |
Baricitinib | Moderate to severe active rheumatoid arthritis in adults who have responded inadequately, or intolerant to one or more DMARDs | Red | |
Baricitinib | Restricted use for systemic autoinflammatory syndrome | Red | WY ICS APC September 2022 |
Baricitinib | Treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy. | Red | 22nd September 2021 (n) |
Baricitinib | Treatment of patients aged 18 years with severe alopecia areata, including alopecia totalis and alopecia universalis (licence extension) - new indication | Do not prescribe/not yet classified | WY ICS APC November 2022 |
Baricitinib | Paediatric indications (where adult NICE TA available) | Red | |
Baricitinib tablets (2mg and 4mg) | For monogenic interferonopathies (Adults and children 2 years and older) | Red | WY ICS APC March 2022 (n) |
Basiliximab | Renal transplant | Red | |
Bath and Shower preparations | Dry and pruritis skin conditions | Do not prescribe | WY ICS APC November 2022 |
BCG vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Bedaquiline | TB | Red | |
Belimumab | Systemic lupus erythematosus (SLE) | Red | |
Bempedoic acid with ezetimibe tablets | For the treatment of primary hypercholesterolaemia or mixed dyslipidaemia when taken in combination with ezetimibe as per NICE TA694. | Green Restricted | WY ICS APC 24th May 2023 |
Bempedoic Acid monotherapy | Use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet, only in exceptional patients who are intolerant to other lipid lowering medicines. | Specialist Recommendation | WY ICS APC Sept 2023 |
Bendamustine | Treatment of cancer (commissioned by NHS England) | Red | |
Benralizumab | Asthma | Red | |
Benzbromarone | Unlicensed medicine - Gout | Red | |
Berotralstat dihydrochloride hard capsules (150mg) | Indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. NICE TA738 | Red | WY ICS APC March 2022 (n) |
Berotralstat | For preventing recurrent attacks of hereditary angioedema NICE TA738 | Red | WY ICS APC April 2022 |
Betaine | Homocystinuria | Red | |
Bevacizumab | All indications | Red | |
Bexarotene | Treatment of cancers | Red | |
Bezafibrate | For treatment of Primary Biliary Cholangitis | Specialist Initiation with additional guidance | WY ICS APC Sept 2023 |
Bicalutamide | Locally advanced prostate cancer at high risk of disease progression. Locally advanced non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate. Ongoing monotherapy for prostate cancer in patients wishing to preserve sexual function. Maximum androgen blockade – use continuously in conjunction with LHRH analogue for three months | Amber | |
Bimatoprost/timolol eye drops (Ganfort®) | Glaucoma | Green Specialist Initiation | |
Bimekizumab 160mg solution for injection in pre-filled pen/syringe | For all indications | Red | WY ICS APC Nov 2023 (a) |
Binimetinib | Treatment of cancers | Red | 4th Sept 2020 |
Biopatch® | Prevention of catheter site infection | Red | |
Biotin | Vitamin induced hair loss. Multiple sclerosis (MS) | Red | |
Bismuth Subsaliylate | Microscopic colitis | Specialist Recommendation | WY ICS APC September 2022 |
Bismuth subsalicylate tablets | For treatment of H pylori | Green | WY ICS APC November 2022 |
Bivalirudin | For the treatment of Acute Coronary Syndrome in line with NICE NG185. | Red | WY ICS APC 24th May 2023 |
Blinatumomab | Treatment of cancers | Red | |
Boceprevir | Hepatitis C (commissioned by NHS England) | Red | |
Bone morphogenic protein (dibotermin, eptotermin) | Complex spinal surgery (commissioned by NHS England) | Red | |
Bortezomib | For Waldenstrom's Macroglobulinemia | Red | WY ICS APC April 2022 |
Bosentan | All indications | Red | |
Bosutinib | Treatment of cancer (commissioned by NHS England) | Red | |
Botulinum toxin | All indications | Red | |
Botulinum toxin injection | For cricopharyngeal spasm in laryngectomy patients | Red | WY ICS APC Chair's action January 2022. |
Brentuximab | Treatment of cancer (commissioned by NHS England) | Red | |
Brexucabtagene autoleucel | For treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. | Red | WY ICS APC July 2023 |
Brigatinib | Treatment of cancer (commissioned by NHS England) | Red | |
Brimonidine gel | Treatment of facial erythema of rosacea in adults | Black | |
Brivaracetam | As an adjunctive third line treatment option for the management of partial-onset seizures with or without secondary generalisation in adults. Brivaracetam may be considered if there is: • failure of one or more first line drugs (carbamazepine, lamotrigine or levetiracetam) AND • failure of one or more 2nd line drugs (topiramate, pregabalin, lacosamide, zonisamide or perampanel) | Green Specialist Initiation | |
Brivaracetam | Partial onset seizures - for paediatric use | Green Specialist Initiation | 20th September 2019 (n) |
Brodalumab | Paediatric indications (where adult NICE TA available) | Red | |
Brodalumab | For moderate to severe plaque psoriasis in adults according to NICE TA511 | Red | |
Brolucizumab 120mg/ml solution for injection intravitreal injection | Licensed for the treatment of neovascular (wet) age-related macular degeneration (AMD) NICE TA672 | Red | WY ICS APC March 2022 (n) |
Budesonide nebuliser liquid | For the treatment of paediatric oesinophilic oesophagitis. .How to make up the liquid | Specialist Initiation with additional guidance | WY ICS APC November 2022 |
Budesonide 1mg orodispersible tablets | For eosinophilic in adults - for short courses upto 6 weeks for an acute episode NICE TA708 | Red | WY ICS APC November 2022 |
Budesonide 1mg orodispersible tablets | For eosinophilic in adults - maintenance course NICE TA708 | Specialist Recommendation | WY ICS APC November 2022 |
Budesonide orodisperisable tablets | For treatment of eosinophilic esophagitis (EoE) in adults | Red | WY ICS APC November 2022 |
Budesonide orodisperiable tablets | For all indications other than treatment of acute or maintenance of oeosinophilic oesophagitis | Do not precribe | WY ICS APC November 2022 |
Budesonide MMX (Cortiment) | In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient | Red | 24th March 2021 (n) |
Budesonide Prolonged Release (Cortiment®) 9mg tablet | For use in ulcerative colitis - requesting a supply during a flare up in line with patients' self-management plan,, maximum 2 courses per year. | Specialist Recommendation | WY ICS APC Nov 2023 |
Bulevirtide | Indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease | Red | WY ICS APC July 2023 |
Bulkamid | Periurethral injection for the management of female stress incontinence | Red | |
Buprenorphine implant | For substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8mg/day of sublingual buprenorphine. This formulation has yet to be reviewed at WY ICS level. | Do Not Prescribe/Not yet classified | WY ICS PC March 2023 (n) |
Buprenorphine prolonged release solution for injection | Treatment of opioid dependence within a framework of medical, social and psychological treatment – adults and adolescents aged 16 years or over. | Red | WY ICS APC March 2023 (n) |
Burosumab | X-linked hypophosphataemia | Red | |
Buserelin | Gonadorelin analogue - IVF | Red | |
Busulfan | Treatment of cancer | Red | |
C1 esterase inhibitors | Hereditary angioedema | Red | |
Cabazitaxel | Treatment of cancer (commissioned by NHS England) | Red | |
Cabotegravir with Rilpivirin | For HIV-1 infection in adults NICE TA757 | Red | WY ICS APC 22nd June 2022 |
Cabozantinib | Treatment of cancer (commissioned by NHS England) | Red | |
Canakinumab | Cryopyrin associated periodic syndrome and juvenile arthritis - paediatric | Red | |
Cabergoline | Parkinson's disease | Green Specialist Initiation | |
Calcifediol | Vitamin D deficiencies | Do not Prescribe/Not yet Classified | WY ICS APC Jan 2024 |
Calcipotriol / betamethasone scalp gel | Psoriasis | Green | |
Canagliflozin | Type 2 diabetes (T2DM) | Green | |
Cannabis-based products (not Sativex®) | See NHS England's Guidance Cannabis-based products | Black | |
Cannabidiol (Epidyolex®) with clobazam | Dravet/Lennox gestaut syndrome | Red | |
Cannabidiol oral solution | All licensed indications | Red | WY ICS APC 20th October 2021 (n) |
Capecitabine | All indications | Red | |
Caphosol® oral rinse | For the prevention and treatment of mucositis caused by high dose chemotherapy | Red | |
Caplacizumab | Thrombotic thrombocytopenic pupura | Red | 4th Sept 2020 |
Capsaicin patches 8% | Neuropathic pain | Red | |
Captopril liquid 5mg/5ml and 25mg/5ml | For all licensed indications and Neonatal Unit and congenital heart disease patients. Green for adults with swallowing difficulties (use most cost-effective product). | Specialist Recommendation | WY ICS APC Sept 2023 |
Captopril liquid 5mg/5ml and 25mg/5ml | For all licensed indications for adults with swallowing difficulties. Specialist Recommendation for all licensed indications and neonatal unit and congenital heart disease patients. | Green | WY ICS APC Sept 2023 |
Carfilzomib | Treatment of cancer (commissioned by NHS England) | Red | |
Carglumic acid | Urea cycle disorders | Red | |
Carnitine | Carnitine deficiency | Red | |
Carnoys solution | Treatment of histological odentogenic keratocysts or recurrences | Red | 22nd January 2020 (n) |
Casirivimab with imdevimab | For intravenous infusion or subcutaneous injection for treating COVID-19 disease | Red | WY ICS APC Chair's action January 2022. |
Caspofungin | Fungal infections | Red | |
Cefiderocol | Multi-drug resistant aerobic gram negative infections on advice of microbiology | Red | WY ICS APC September 2022 |
Cemiplimab | Treatment of Cancers | Red | 4th Sept 2020 |
Ceritinib | All indications | Red | |
Cerliponase alfa | Neuronal ceroid lipofuscinosis | Red | |
Certolizumab pegol | All indications | Red | |
Cetrorelix | IVF | Red | |
Cetuximab | Treatment of cancer (commissioned by NHS England) | Red | |
Chenodeoxycholic acid | Cerebrotendinous xanthomatosis and primary biliary cirrhosis | Red | |
Chloral Hydrate | Insomnia (Short term use) | Red | |
Chloral Hydrate (oral) | For paediatric neurology and palliative care | Green Specialist Initiation | |
Chlorambucil | Benign angiitis of the CNS | Red | |
Chlordiazepoxide | Acute alcohol withdrawal | Red | |
Chlormethine 160mg/g gel | Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults NICE TA720 | Red | WY ICS APC March 2022 (n) |
Cholic acid | Inborn errors in primary bile acid synthesis | Red | |
Chondroitin | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Chondriotin sulphate | Bladder instillation for Patients with damaged or glycosaminoglycan deficient bladder epithelium | Red | |
Chorionic gonadotrophin | Gonadorelin analogue - IVF | Red | |
Ciclosporin | Inflammatory bowel disease | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Ciclosporin | Licensed indications: rheumatoid arthritis, psoriasis. Off-label indication: psoriatric arthritis | Amber | |
Ciclosporin | Dermatological conditions. Licensed: atopic dermatitis. Off-label: bullous pemphigoid, pyoderma gangrenosum, hidradenitis suppurativa, pemphigus & lupus | Amber | |
Ciclosporin | Bone marrow transplant | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Ciclosporin | Paediatric Rheumatology | Amber | |
Ciclosporin | Post-transplant | Amber | |
Ciclosporin eye drops 1mg/mL (0.1%) (Verkazia) | Treatment of severe Vernal Keratoconjunctivitis (VKC) in children from 4 years to adolescents - licensed | Specialist Initiation | WY ICS APC November 2022 |
Ciclosporin eye drops 1mg/ml (Ikervis®) | For severe keratitis in adult patients with dry eyes as per NICE TA369 | Specialist Initiation | WY ICS APC March 2023 (n) |
Cidofovir | Cytomegalovirus | Red | |
Cinacalcet | Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma | Amber Cinacalcet | WY ICS APC November 2022 (a) |
Cinacalcet | Secondary hyper-parathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | Amber | |
Cipaglucosidase alfa | For treating late onset Pompe disease (with migluslat) NICE TA912 | Red | WY ICS APC Nov 2023 |
Cisplatin 1mg/ml injection | For nasopharyngeal cancer | Red | WY ICS APC March 2022 (n) |
Cladribine | Multiple sclerosis (MS) | Red | |
Clofarabine | Treatment of cancer (commissioned by NHS England) | Red | |
Clofazimine | Antimycobacterial | Red | WY ICS APC November 2022 |
Clomifene | IVF treatment | Red | |
Clonidine patches | For children with ongoing new developmental problems including dystonia. Please note that patches were previously Specialist Initiation (Amber 2) in Leeds, unclassified in South West Yorkshire. Guidance on the use for dystonia in children is being updated to reflect this change. Oral preparations for dystonia remain specialist initiation. Please note these classifications only apply to the use of clonidine in dystonia. There are other indications for clonidine - see local formularies. | Red | WY ICS APC March 2023 (n) |
Clopidogrel | For all licensed indications | Green | WY ICS APC 24th May 2023 |
Clozapine | Atypical Antipsychotic - Schizophrenia | Red | |
CoaguCheK | For paediatric haematology - Peadiatric haematology patients managed by the Leeds anticoagulant service only. | Specialist Initiation Restricted | WY ICS APC 24th May 2023 |
CoaguChek | For adults who are on long-term vitamin K antagonist therapy wh have atrial fibrillation or heart valve disease | Red | WY ICS APC 24th May 2023 |
Cobicistat | HIV infection (commissioned by NHS England) | Red | |
Co-careldopa intestinal gel | Severe Parkinson's disease | Red | |
Co-Enzyme Q10 | Enzyme deficiency in children | Red | |
Colesevelam | Hyperlipidaemia | Green | |
Colesevelam | For pruritus in liver disease - unlicensed. Unlicensed for the treatment of bile acid malabsorption | Specialist Recommendation | WY ICS APC April 2022 |
Colestilan | Renal dialysis - adults | Red | |
Colestyramine sachets | For pruritus in liver disease (historic use) | Green | WY ICS APC Chair's action January 2022. |
Colief® drops | Colic | Black | 30th September 2020(a) |
Colistimethate sodium - (Colomycin®) | Cystic fibrosis (CF) management | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Colistimethate sodium - (Promixin®) | Cystic fibrosis (CF) management | Amber | |
Colistimethate sodium - (Colomycin®) | Pseudomonas infection in the lungs | Amber | |
Conestat alfa | Hereditary angioedema | Red | |
Co-proxamol | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Cough and cold remedies | For treating coughs and colds unless the patient meets one or more of the exception critieria. | Do Not Prescribe | WY ICS APC Nov 2023 (a) |
Crizanlizumab | Indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate | Red | WY ICS APC March 2022 (n) |
Crizotinib | Treatment of cancer (commissioned by NHS England) | Red | |
Cyanocobalamin (oral) | For the treatment of vitamin B12 deficiency, pernicious anaemia associated with vitamin B12 deficiency. | Green | WY ICS APC 24th May 2023 |
Cyclophosphamide | All Indications | Red | |
Cyproheptadine | For use as an appetite stimulant in paediatric patients | Red | WY ICS APC Jan 2024 |
Cyproterone | Prostate cancer and male hypersexuality. | Red for new patients Amber for existing patients only Amber | |
Cyproterone (off-label indications) | Off-label indications | Red | |
Cyproterone | Anti-androgen for gender dysphoria | Amber LHTH | 20th September 2019 (n) |
Cysteamine (mercaptamine) | Nephropathic cystinosis | Red | |
Cytisine oral | Used in the treatment of smoking cessation | Do not Prescribe/not yet classified | WY ICS APC Jan 2024 |
Cytotoxic injectable drugs | All indications | Red | |
Dabigatran | See DOACs | See DOACs | |
Dabrafenib | Treatment of cancer | Red | |
Dabrafenib | For histiocytic disorders | Red | WY ICS APC April 2022 |
Daclatasvir | Hepatitis C (commissioned by NHS England) | Red | |
Daclizumab | Multiple sclerosis (MS) | Red | |
Dacomitinib | Treatment of cancers | Red | 4th Sept 2020 |
Dalbavancin | Acute bacterial skin and skin structure infections in adults | Red | 24th March 2021 (n) |
Danazol (unlicensed) | Aplastic anaemia | Red | 29th July 2020 (n) |
Danazol | The treatment of Hereditary Angioedema (HAE) | Amber LTHT guidance | July 2021 (n) |
Dapagliflozin | Type 2 diabetes (T2DM) | Green | |
Dapagliflozin | For treating chronic heart failure with preserved or mildly reduced ejection fraction. In line with NICE TA902. Please note: This drug must be recommended by a specialist with the relevant experience/expertise and may not necessarily be a prescriber. | Specialist Recommendation | WY ICS APC Nov 2023 (a) |
Dapagliflozin | For treating chronic heart failure with reduced ejection fraction. In line with NICE TA679. Please note: This drug must be recommended by a specialist with relevant experience/expertise and may not necessarily be a prescriber. | Specialist Recommendation | WY ICS APC Nov 2023 (a) |
Dapagliflozin | For treating chronic kidney disease – NICE TA775 | Green Restricted | WY ICS APC 22nd June 2022 |
Dapagliflozin | For children under 10 years with CKD and proteinuria | Do Not Prescribe | WY ICS APC Nov 2023 |
Dapagliflozin | For children 10 years old up to puberty with CKD and proteinuria | Red | WY ICS APC Nov 2023 |
Dapagliflozin | For children post puberty until 18 years with CKD and proteinuria. | Specialist Initiation | WY ICS APC Nov 2023 |
Dapoxetine | Premature ejaculation | Black | |
Dapsone | Licensed indication- Dermatitis herpetiformis, and off-label indications - dermatoses (leucocytoclastic vasculitis, Sweet's syndrome, pyoderma gangrenosum) | SWYAPC | 31st July 2019 (a) |
Daratumunab | Treatment of cancer (commissioned by NHS England) | Red | 31st July 2019 (n) |
Daratumumab | All oncology indications | Red | WY ICS APC Jan 2024 |
Daratumumab | For transplant eligible, newly diagnosed myeloma in combination with thalidomide and dexamethasone | Red | WY ICS APC September 2022 |
Daratumumab plus bortezomib, thalidomide and dexamethasone | As induction and consolidation treatment for untreated multiple myeloma in adults, when an autologous stem cell transplant is suitable NICE TA763 | Red | WY ICS APC April 2022 |
Darbepoetin alfa | All indications | Red | |
Daridorexant | For treating long-term insomnia in line with NICE TA922 (Insomnia pathway in development) | Green Restricted | WY ICS APC Nov 2023 |
Darolutamide | Treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease | Red | 24th March 2021 (n) |
Darunavir | HIV infection (commissioned by NHS England) | Red | |
Darunavir/cobicistat | HIV infection (commissioned by NHS England) | Red | |
Dasabuvir | Hepatitis C (commissioned by NHS England) | Red | |
Dasatinib | Treatment of cancer (commissioned by NHS England) | Red | |
Daunorubicin | Treatment of cancer (commissioned by NHS England) | Red | |
Deferasirox | Iron chelation in thalassaemia and sickle cell | Red | |
Deferiprone | Iron chelation in thalassaemia and sickle cell | Red | |
Defibrotide | Hepatic veno-occlusive disease | Red | |
Delafloxacin | Treatment for acute bacterial skin and skin structure infections (ABSSSI) when standard treatments are not suitable (in line with trust approved guidelines and microbiology advice) | Red | WY ICS APC November 2022 |
Delamanid | Extensively drug-resistant TB and multi drug-resistant TB | Red | |
Denosumab | Prevention of osteoporosis | Amber SWYAPC | |
Denosumab | Prevention of skeletal events from breast cancer | Red | |
Dental products on FP10 | Black with the exception of those patients on specialist advice following treatment for head and neck cancers (GSI) See NHSE Guidance on the conditions for which over the counter items should not routinely be prescribed in primary care. | ||
Dequalinium chloride | Bacterial vaginosis | Red | 31st July 2019 (n) |
Deferasirox (oral) | For treating chronic iron overload | Red | WY ICS APC November 2022 |
Desiccated thyroid products (Armous/ERFA). | Hypothyroidism | Do not prescribe | WY ICS APC July 2023 |
Desmopressin | For nocturnal enuresis in children (By any specialist practitioner (within paediatrics (community or hospital) or School Nursing) | Specialist Recommendation | WY ICS APC April 2022 |
Deucravacitinib | For treating moderate to severe plaque psoriasis – Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC Sept 2023 |
Dexamethasone intravitreal implant | Macular oedema | Red | |
Dexamfetamine | For attention-deficit hyperactivity disorder (ADHD) in adults only. | Amber | WY ICS APC July 2023. |
Dexamfetamine and lisdexametamine | For attention deficit hyperactivity disorder (ADHD) in school-age children, adolescents .To use only for children only until new guidance is produced. For adults use the new APC guidance. | Amber | |
Dexcom 1 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Specialist Recommendation | Chair's Action ICS APC May 2023 |
Dexcom G6 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Dexcom G7 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Dexmedetomide | Maintenance of sedation during intensive care | Red | |
Dexrazoxane | Anthracycline extravasation and cardiotoxicity (NHS England) | Red | |
Dibotermin alfa | Complex spinal surgery (commissioned by NHS England) | Red | |
Dicycloverine hydrochloride | To treat irritable bowel syndrome (IBS) minor diarrhoea and dysmenorrhoea _ for new patients only | Do not prescribe | WY ICS APC November 2022 |
Didanosine | HIV infection (commissioned by NHS England) | Red | |
Dienogest tablets | For endometriosis | Specialist Recommendation | WY ICS APC September 2022 |
Dihydrotestosterone (Androstanolone®) | Unlicensed - recommendation from Leeds paediatric surgeons | Red | |
Difelikefalin | Indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. | Red | WY ICS APC July 2023 |
Diltiazem Hydrochloride 2% cream | For the treatment of chronic anal fissures (not licensed for this indication) in adults only. Consider GTN as first line. | Green Restricted | WY ICS APC November 2022 |
Dimethyl fumarate | Multiple sclerosis (MS)/psoriasis (commissioned by NHS England) | Red | |
Dinoprostone vaginal delivery system | Cervical ripening/induction of labour | Red | |
Dinutuximab | Treatment of cancer (commissioned by NHS England) | Red | |
Dinutuximab | For treating severe asthma in adolescents over 12 years and adults | Red | WY ICS APC Nov 2023 |
Diroximel | For treating relapsing-remitting MS NICE TA794 | Red | WY ICS APC November 2022 |
Disodium pamidronate (IV) | Bisphosphonate - all licensed indications | Red | |
Disulfiram | Management of patients with drinking problems | Disulfiram | March 2021 (a) |
DOAC (Apixaban, Edoxaban) | Apixaban is the most cost effective DOAC and is recommended 1st Line for AF patients suitable for a twice a day DOAC. Edoxaban is the most cost effective ONCE a day DOAC and is recommended 1st Line for AF patients who require a one daily option where: - Weight <120kg and BMI <40kg/m2; CrCl <95mLs/min: NOTE: edoxaban is not suitable for 12 months post percutaneouos coronary intervention (PCI) | Apixaban is the most cost effective DOAC and is recommended 1st Line for AF patients suitable for a twice a day DOAC. Edoxaban is the most cost effective ONCE a day DOAC and is recommended 1st Line for AF patients who require a one daily option where: - Weight <120kg and BMI <40kg/m2; CrCl <95mLs/min: NOTE: edoxaban is not suitable for 12 months post percutaneouos coronary intervention (PCI) | NHS England - National procurement for DOACs WY ICS APC Jan 2024 |
DOACs (Apixaban, Dabigatran etexilate, Edoxaban, Rivaroxaban) | Red for prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. Red for acute coronary syndrome (ACS). Full courses supplied through Acute Trust. GSI for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, subject to local policy. Specialist Initiation Restricted for treatment of left ventricular thrombus (off-label). Green for switching between DOACs for the treatment of acute or recurrent venous thromboembolism (VTE) where patients are established on DOAC therapy for clinical reasons or patient preference. Green for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, with one or more risk factors, subject to local policy. Green for the reduction of stroke risk for patients with atrial fibrillation (AF). Edoxaban 1st line for new AF patients where weight <120kg;CrCl<95mLs/min;patient is suitable for any DOAC or any once daily DOAC. Check licensed indications and doses of individual drugs | Red for prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. Red for acute coronary syndrome (ACS). Full courses supplied through Acute Trust. GSI for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, subject to local policy. Specialist Initiation Restricted for treatment of left ventribular thrombus (off-label). Green for switching between DOACs for the treatment of acute or recurrent venous thromboembolism (VTE) where patients are established on DOAC therapy for clinical reasons or patient preference. Green for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, with one or more risk factors, subject to local policy. Green for the reduction of stroke risk for patients with atrial fibrillation (AF). Edoxaban 1st line for new AF patients where weight <120kg;CrCl<95mLs/min;patient is suitable for any DOAC or any once daily DOAC. Check licensed indications and doses of individual drugs | WY ICS APC 24th May 2023 |
DOACs (Rivaroxaban) | For VTE prevention in diabetic limb salvage patients with off-loading casts due to diabetic foot ulcers/Charcot foot. Prevent of venous thromboembolic event (VTE) in adults who have undergone elective hip or knee replacement surgery NICE TA157. Antiplatelet therapy for percutaneous coronary intervention (PCI) for adults with aspirin allergy. For prevention of venous thromboembolism (VTE) in patients who are immobilised with lower leg casts (unlicensed use) | Red | WY ICS APC 24th May 2023 |
DOACs (Rivaroxaban) | For preventing adverse outcomes after acute management of acute coronary syndrome (ACS) | Specialist Initiation | WY ICS APC 24th May 2023 |
Docetaxel | Advanced/metastatic breast cancer, prostate cancer | Red | |
Dolutegravir | HIV infection (commissioned by NHS England) | Red | |
Domperidone | For use in breast feeding to increase milk production for short term use. The specialist may not always be a prescriber | Specialist Recommendation | WY ICS APC Nov 2023 |
Donepezil | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation | |
Dornase alfa | For treating Cystic fibrosis in adults and children | LTHT guidance Specialist Initiation with additional guidance | WY ICS APC Nov 2023 (a) |
Dornase alfa | For treating Primary ciliary dyskinesia | Do Not Prescribe | WY ICS APC Nov 2023 (a) |
Doravirine | HIV infection (commissioned by NHS England) | Red | |
Dostarimab | For previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency NICE TA779 | Red | ICS APC November 2022 |
Dosulepin | All indications | Black for new patients for all indications NHSE items that should not be routinely prescribed in Primary Care | |
Doxazosin MR | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Doxylamine (Xonvea®) | Nausea and vomiting in pregnancy | Back not yet classified | |
Dronedarone | For the treatment of severe cardiac rhythm disorders as a second line option | Dronedarone | WY ICS APC May 2023 |
Dronedarone | For the treatment of non-permanent Atrial Fibrillation in line with NICE TA197. | Dronedarone | WY ICS APC Sept 2023 |
Droperidol injection | Post operative nausea and vomiting | Red | |
Dulaglutide | Type 2 diabetes | Green | |
Duloxetine | Pain - nerve | Green | |
Dupilumab | Asthma | Red | |
Dupilumab | For treating severe asthma with type 2 inflammation NICE TA751 | Red | ICS APC April 2022 |
Durvalumab | Cancer | Red | 27th November 2019 (n) |
Dutasteride | For benign prostatic hyperplasia (BPH) (2nd line to finasteride) | Green Restricted | ICS APC November 2022 |
Eculizumab | All indications | Red | |
Edoxaban | See DOACs | See DOACs | |
Edoxaban | For the prevention of venous thrombo-embolism (VTE) in patients with myeloma (ULM) | Red | WY ICS APC Nov 2023 |
Efavirenz | HIV infection (commissioned by NHS England) | Red | |
Eflornithine cream | For Hirsuitism | Black | 28th July 2021 (a) |
Eladocagene exuparvovec | For treating aromatic L-amino acid decarboxylase deficiency. | Red | WY ICS APC July 2023 |
Eliglustat | Gaucher's disease | Red | |
Elosulfase alfa | Mucopolysacchardosis IV type A | Red | |
Eltrombopag | Immune (idiopathic) thrombocytopenic purpura | Red | |
Elvitegravir | HIV infection (commissioned by NHS England) | Red | |
Emicizumab | As per BCSH guidelines for specialised indications | Red | |
Empagliflozin | For treating Type 2 diabetes NICE TA336 & 390 | Green | 27th November 2019 (n) |
Empagliflozin | For treating chronic heart failure with reduced ejection fraction NICE TA773 | Specialist Recommendation | ICS APC September 2022 |
Empagliflozin | For treating chronic heart failure with preserved or mildly reduced ejection fraction NICE TA929 | Specialist Recommendation | WY ICS APC Nov 2023 |
Emtricitabine | HIV infection (commissioned by NHS England) | Red | |
Emtricitine/rilpivirine/tenofovir alafenamide | HIV infection (commissioned by NHS England) | Red | |
Emtricitine/rilpivirine/tenofovir alafenamide | HIV infection (commissioned by NHS England) | Red | |
Emtricitine/tenofovir/darunavir/cobicistat | HIV infection (commissioned by NHS England) | Red | |
Emtricitine/tenofovir/elvitegravir/cobicistat | HIV infection (commissioned by NHS England) | Red | |
Encorafenib | Treatment of cancers | Red | 4th Sept 2020 |
Enfuvirtide | HIV infection (commissioned by NHS England) | Red | |
Enstilar® (calcipotriol and betamethasone) | Psoriasis | Green if failed on individual components | |
Entecavir | Chronic Hepatitis B infection | Red | |
Enzalutamide | For treating hormone-sensitive metastatic prostate cancer NICE TA712 | Red | ICS APC April 2022 |
Epoetin (all variants) | All indications | Red | 22nd January 2020 from Amber |
Epoprostenol | Off-label indications. | Red | WY ICS APC 24th May 2023 |
Eptinezumab | For prophylaxis of migraine in adults as per NICE TA871. | Red | WY ICS APC 24th May 2023 |
Eptotermin alfa | Complex spinal surgery (commissioned by NHS England) | Red | |
Erdoseine | For treating Chronic Obstructive Pulmonary disease (COPD) | Do Not Prescribe | WY ICS APC Nov 2023 |
Erenumab | For prophylaxis of migraine in adults who have at least 4 migraine days per month | Red | 22nd September 2021 (a) was Black since16.10.19 |
Eribulin | Treatment of cancers | Red | |
Erlotinib | Treatment of cancers | Red | |
Ertapenem | For antimocrobial use | Red | WY ICS APC July 2023 |
Ertugliflozin | Type 2 diabetes | Green | 31st July 2019 (n) |
Esketamine Nasal spray | For major depressive disorders | Do not Prescribe | WY ICS APC Jan 2024 |
Eslicarbazepine | Epilepsy | Green Specialist Initiation | |
Esomeprazol injection | For use in short bowel/intestinal failure patients who are to be discharged on an intravenous proton pump inhibitor | Red | ICS APC 20th October 2021 (n) |
Estradiol transdermal spray | HRT for oestrogen deficiency symptoms in postmenopausal women | Green | WY ICS APC 22nd June 2022 |
Etanercept | All indications | Red | |
Etelcalcetide | Hyperparathyroidism -dialysis patients only | Red | |
Ethambutol | Treatment of TB | Red | |
Etravirine | HIV infection (commissioned by NHS England) | Red | |
Etrolizumab | Paediatric indications (where adult NICE TA available) | Red | |
Everolimus (Afinitor®) | Treatment of cancers | Red | |
Everolimus (Votubia®) | Tubular sclerosis | Red | |
Evicel® | Tissue adhesive - for use in patients undergoing pelvic surgery or laparoscopic partial nephrectomies | Red | |
Evolocumab | Homozygous familial hypercholesterolaemia | Red | |
Exemestane | Breast Cancer | Green Specialist Initiation | |
Exenatide | Type 2 diabetes (T2DM) | Green | |
Exenatide weekly | Type 2 diabetes (T2DM) | Green | |
Ex-vivo expanded autologous human corneal epithelial cells containing stem cells | Limbal stem cell deficiency | Red | |
Factor IX | As per BCSH guidelines for specialised indications | Red | |
Factor VII | As per BCSH guidelines for specialised indications | Red | |
Factor VIIa (Recombinant) (NovoSeven®) | Bleeding episodes in surgery in specific patients | Red | |
Factor VIIa | As per BCSH guidelines for specialised indications | Red | |
Factor VIII | As per BCSH guidelines for specialised indications | Red | |
Factor VIII inhibitor bypassing factor | As per BCSH guidelines for specialised indications | Red | |
Factor X | Hereditary factor X deficiency | Red | |
Factor XIII | As per BCSH guidelines for specialised indications | Red | |
Faricimab solution for injection | For treating diabetic macular oedema & wet age-related macular degeneration | Red | ICS APC September 2022 |
Favipiravir | For chronic norovirus in adults with primary immunodeficiency | Red | ICS APC September 2022 |
Febuxostat | For patient's intolerant of allopurinol or allopurinol contradicted in line with NICE TA164 | Green Restricted | ICS APC September 2022 |
Fedratinib | Myelofibrosis | Red | 4th Sept 2020 |
Fedratinib | For treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis in adults NICETA756 | Red | ICS APC April 2022 |
Female stress incontinence devices | For urinary incontinence in women according to NICE NG123 | Specialist Recommendation | ICS APC November 2022 |
Fenfluramine | Dravet Disease | Red | 4th Sept 2020 |
Fentanyl nasal spray | Pain relief - use should be restricted to palliative care consultants | Green Specialist Initiation | |
Fentanyl IR | For non palliative care indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Ferric carboxymaltose | Iron-deficiency anaemia | Red | |
Ferric carboxymaltose | Heart failure patients with or without decreased haemoglobin levels | Red | WY ICS APC 24th May 2023 |
Fesoterodine | Overactive bladder syndrome | Green | |
Fexofenadine oral | Chronic spontaneous urticarial and angioedema (For 12 yrs and over) | Green | 29th July 2020 (n) |
Fexofenadine oral | Chronic spontaneous urticarial and angioedema (For 11years and younger) | Green Specialist Initiation | 29th July 2020 (n) |
Fezolinetant | For treating hot flushes associated with the menopause. | Do not Prescribe/Not yet Classified | WY ICS APC Jan 2024 |
Fiasp® (insulin aspart) | Treatment of diabetes in adult patients with Type 1 diabetes who are likely to benefit directly from a more rapid onset of action, including: 1.Pregnancy 2.Use of insulin pump 3.Young adults unable to manage with Novorapid because of poor post-prandial glucose control, despite adequate therapeutic trial | Green Specialist Initiation | |
Fibrinogen | As per BCSH guidelines for specialised indications | Red | |
Fidaxomicin | Treatment of Clostridium difficile infection only when it prevents admission to hospital or severe illness | Green Specialist Initiation | |
Filgotinib | For the treatment of moderate and severe RA | Red | 22nd September 2021 (n) |
Filgotinib | Paediatric indications (where adult NICE TA available) | Red | |
Filgrastim | Neutropenia and Barth syndrome | Red | |
Finasteride | For the treatment of male pattern baldness | Do not prescribe | ICS APC November 2022 |
Finasteride | For benign prostatic hyperplasia | Green | ICS APC November 2022 |
Finerenone | For treating stage 3 and 4 chronic kidney disease with albuminuria in type 2 disbetes in adults. | Specialist Initiation with additional guidance | WY ICS APC January 2024 |
Fingolimod | Management of multiple sclerosis | Red | |
Flash glucose monitoring systems | Type 1 diabetes mellitus for patients who fulfil the criteria | Green Specialist Initiation | |
Flebogamma® | All indications | Red | |
Flebogammadif® | All indications | Red | |
Flecainide Injection | For treatment of arrhythmias (ventricular and supraventricular) unlicensed – Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC Sept 2023 |
Flecainide Oral | For treatment of tachyarrhythmias | Specialist Initiation | WY ICS APC Sept 2023 |
Fludarabine | Treatment of cancers | Red | |
Fludrocortisone | Leeds Guidelines Orthostatic (Postural) Hypotension | Green Restricted | ICS APC November 2022 |
Flunarizine capsules | For alternating hemiplegia of childhood | Red | ICS APC Chair's action January 2022. |
Fluocinolone acetonide intravitreal implant | Treatment of chronic diabetic macular oedema | Red | |
Fluorouracil/salicylic acid (Actikerall®) | Management of actinic keratosis | Green | |
Flupentixol depot injection | Depression | Specialist Initiation | WY ICS APC Jan 2024 |
Fluphenazine depot injection | Depot antipsychotic for schizophrenia (to be discontinued at the end of 2018 - no new patients should be started on this if treatment is expected to continue beyond 2018) | Green Specialist Initiation | |
Fluticasone propionate/azelastine hydrochloride nasal spray | Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis | Green | May 2021 (a) |
Follitropin alfa/beta | IVF - Gonadotrophin | Red | |
Fondaparinux | Parenteral anticoagulant | Red | |
Fosaprepitant injection | Chemotherapy induced nausea and vomiting | Red | |
Foscarbidopa & foslevodopa | For treating advanced Parkinson's with motor symptoms | Red | WY ICS APC Jan 2024 |
Foscarnet | Cytomegalovirus | Red | |
Fosfomycin IV | 2nd line antibiotic for patients with carbapenemase resistant infections or with confirmed anaphylactoid reaction to penicillins presenting with suspected meningitis | Red | |
Fosfomycin (Oral) | Antibiotic to be prescribed as per antimicrobial guidelines for the treatment of UTI. | Green | WY ICS APC March 2023 |
Fosfomycin Oral | For treating cystic fibrosis in adults and children over 12. | Green | WY ICS APC Nov 2023 |
Fosfomycin injection | For treating cystic fibrosis in adults and children over 12. Oral fosfomycin is Green | Red | WY ICS APC Nov 2023 |
Fostamatinib | For refractory chronic immune thrombocytopenia as per NICE TA835. Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC March 2023 (n) |
Fremanezumab | Migraine | Red | 16.10.19 changed from Black to Red 29th July 2020 (a) |
Freestyle Libre 2 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Specialist Recommendation | Chair's Action ICS APC May 2023 |
Freestyle Libre 3 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Fulvestrant | Breast cancer | Red | |
Fulvestrant | For the treatment of estrogen receptor positive, locally advanced, or metastatic breast cancer in postmenopausal women. To be used as monotherapy. | Red | ICS APC November 2022 |
Gabapentin 6% Topical gel | For vulvodynia | Red | ICS APC Chair's action January 2022. |
Galantamine | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation | |
Galcanezumab | Treatment for migraine prophylaxis | Red | ICS APC 20th October (a) from SWYAPC was Black 16.10.19 |
Galsulfase | Mucopolysaccharidosis | Red | |
GammaCore ® | Red for Cluster Headaches Black for all other indications | Red | 18th March 2020 (n) |
Gammagard® | All indications | Red | |
Gammanorm® | All indications | Red | |
Gammaplex® | All indications | Red | |
Gamunex® | All indications | Red | |
Ganciclovir | Cytomegalovirus (CMV) | Red | |
Ganirelix | For the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART). Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice | Red | WY ICS APC March 2023 (n) |
Gefitinib | Treatment of cancers (commissioned by NHS England) | Red | |
Gemcitabine | Treatment of cancer (commissioned by NHS England) | Red | 31st July 2019 (n) |
Gemcitabine injection | For nasopharyngeal cancer | Red | ICS APC March 2022 (n) |
Gemtuzumab ozogamicin | Treatment of cancers (commissioned by NHS England) | Red | |
Gender dysphoria or reassignment drugs | Guidance available from Leeds Health Pathways (search 'gender') | See Information from Leeds Health Pathway | |
Glatiramer | Multiple sclerosis (MS) | Red | |
Glecaprevir/pibrentasvir | Indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older - NICE TA499 | Red | ICS APC September 2022 |
Glofitamab | For treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | Red | WY ICS APC Jan 2024 |
Glucosamine | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Glucarpidase | Methotrexate-induced renal dysfunction | Red | |
Glucagon injection (GlucaGen Hypokit) | Available for use in primary care. Secondary care to supply if appropriate according to MSN. Indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 2 and over with diabetes mellitus. To be reviewed in April 2024. | Green Restricted | WY ICS APC Jan 2024 |
Glucagon injection (Ogluo) - for existing patients | Available in secondary care if required to conserve supplies of GlucaGen Hypokit in line with MSN shortage advice. Indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 2 and over with diabetes mellitus. | Red | WY ICS APC Jan 2024 |
Glucagon injection(Ogluo) - for new patients | Do not prescribe in Primary Care, sufficient supplies of GlucaGen Hypokit are available. Indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 2 and over with diabetes mellitus. | Do not Prescribe | WY ICS APC Jan 2024 |
GlucaMen Day | CGM Device | Do not Prescribe | Chair's Action WY ICS APC August 2023 |
GlucoRx Aidex | All indications | Do not Prescribe | Chair's Action ICS APC May 2023 |
Glycerol phenylbutyrate | Urea cycle disorders | Red | |
Glycopyrronium Bromide (oral) | Hypersalivation (adults and children) LTHT guidance for information | Green Specialist Initiation | May 2021 (a) |
Glycopyrronium (topical) | Hyperhidrosis | Red | |
GnRH analogues (Leuprorelin or Triptorelin) | Endometriosis or uterine fibroids | Amber | |
GnRH analogues (Goserelin, Leuproelin, Triptorelin, Degarelix) | Management of prostate cancer | Amber | |
Golimumab | All indications | Red | |
Gonadorelin | IVF - hypothalmic hormone | Red | |
Gonasi brand only (Chorionic Gonadotrophin) | As a sourced alternative as Pregnyl brand hCG has been discontinued for hypogonadotropic hypogonadism in men | Red | ICS APC September 2022 |
Goserelin | Management of prostate cancer | Amber - see GnRH analogues | |
Goserelin | IVF - gonadorelin analogue | Red | |
Goserelin | Endometriosis | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Goserelin | For breast cancer | Green Specialist Initiation | |
Grazoprevir and Elbasvir | Hepatitis C (commissioned by NHS England) | Red | |
Grazax® | Seasonal allergic hayfever | Red | |
Guanfacine | Attention deficit hyperactivity disorder (ADHD) in school age children, adolescents and adults | Amber | Currently under RMOC consultation and will update accordingly - July 2021 |
Guselkumab | For moderate to severe plaque psoriasis in adults according to NICE TA521 | Red | |
Haloperidol depot injection | Depot antipsychotic for schizophrenia | Green Specialist Initiation | |
Haemorrhoid preparations available over-the-counter | Treatment of haemorrhoids | Black | 28th July 2021 (a) |
Herbal | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Hepatitis B vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Hizentra® | All indications | Red | |
Homeopathic medicines | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Human (haem) arginate | Hepatic porphyria | Red | |
Human Coagulation Factor X | Factor X Deficiency | Red | 4th Sept 2020 |
Human fibrinogen | Treatment of bleeding in patients with congenital hypo, or afibrinogenemia with bleeding tendency | Red | ICS APC November 2022 |
Human menopausal gonadotrophins | IVF - Gonadotrophin | Red | |
Human Papillomavirus | Prevention of premalignant genital and anal lesions, cervical and anal cancers and genital | Green | ICS APC April 2022 |
Hyaluronic acid derivatives (injectables) | Osteoarthritis and other joint conditions | Black | |
Hyaluronic acid injection | Specialist use on local trust formularies only | Red | ICS APC November 2022 |
Hydrocortisone m/r capsules (Efmody) | For the treatment of congenital adrenal hyperplasia | Specialist Inititation | WY ICS APC 24th May 2023 |
Hydrocortisone m/r tablets | Adult and paediatric adrenal insufficiency | Do not precribe | WY ICS APC 24th May 2023 |
Hydrocortisone standard release tablets | For the treatment of paeidatric adrenal insufficiency | Specialist Initiation | WY ICS APC 24th May 2023 |
Hydrocortisone standard release tablets | For adrenal insufficiency in adults | Specialist Recommendation | WY ICS APC 24th May 2023 |
Hydrocortisone rectal foam | For treatment of ulcerative colitis | Specialist Recommendation | ICS APC November 2022 |
Hydroquinone/tretinoin/hydrocortisone cream (Pigmanorm) | Hyperpigmentation (ULM). Also classified as Do Not Prescribe for melasma | Red | WY ICS APC July 2023. |
Hydroquinone/tretinoin/hydrocortisone cream (Pigmanorm) | Do not prescribe for Melasma. Also classified as Red for hyperpigmentation (ULM) | Do not prescribe | WY ICS APC July 2023. |
Hydroxycarbamide | Treatment of solid tumours | Red | |
Hydroxycarbamide | Treatment of Polycythaemia, Thrombocythaemia, Chronic Myeloid Leukaemia (CML) and Psoriasis | Amber LTHT guidance for information | May 2021 (a) |
Hydroxycarbamide | Treatment of Psoriasis in adults | Amber LTHT guidance for information | May 2021 (a) |
Hydroxychloroquine | Interstitial Pneumonitis in children | Green Specialist Initiation see LTHT guidance for information | |
Hydroxychloroquine | Paediatric Rheumatology | Green Specialist Initiation See LTHT guidance for information | |
Hydroxychloroquine | Rheumatoid arthritis, systemic and discoid lupus erythematosus (and related connective tissue diseases – off-label) | WY ICS APC guidance | Updated at ICS APC April 2022. Currently under RMOC consultation and will update accordingly |
Hyqvia® | All indications | Red | |
Ibandronic acid tablets 50mg | Post-menopausal women with breast cancer | Green Specialist Initiation | |
Ibandronic acid injection | Bisphosphonate - all licensed indications | Red | |
Ibrutinib | Treatment of cancers | Red | |
Icatibant | For Bradykinin-medicated Angioedema | Red | WY ICS APC July 2023. |
Icosapent ethyl | Indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglyceride | Green Restricted | ICS APC November 2022 |
Idarubicin | Treatment of cancers | Red | |
Idelalisib | Treatment of cancers | Red | |
Idursulfase | Mucopolysaccharidosis | Red | |
Iloprost | Pulmonary arterial hypertension | Red | |
Imatinib mesilate | All indications | Red | |
Imiglucerase | Enzyme replacement - Gaucher's disease | Red | |
Imipenem/cilastatin/relebactam powder | For Gram-negative bacterial infections | Red | ICS APC Chair's action January 2022. |
Imipramine | For nocturnal enuresis in children | Specialist Initiation | ICS APC April 2022 |
Imiquimod | Anogenital warts and basal cell carcinoma | Green Specialist Initiation | |
Imlifidase | Transplant rejection prevention in HLA-sensitised patients | Red | 4th Sept 2020 |
Immunoglobulin - Intravenous (IVIg) | All indications | Red | |
Inclisiran | An option for primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE | Green Restricted | 27th September 2021 (Chair’s action, n) |
Indinavir | HIV infection (commissioned by NHS England) | Red | |
Indocyanine dye | Ophthalmology | Red | |
Infliximab | All indications | Red | |
Inotersen | Amyloidosis | Red | |
Inotuzumab ozogamicin | Treatment of cancers (commissioned by NHS England) | Red | |
Insulin degludec | Diabetes mellitus (DM) | Green Specialist Initiation | |
Insulin glargine (Abasaglar®) | Diabetes mellitus (DM) | Green | |
Insulin glargine (Toujeo®) | Diabetes mellitus (DM) | Green | |
Insulin - Humulin R® - U500 | 500 unit/mL insulin for use in severely insulin resistant patients | Red | |
Insulin lispro (Lyumjev®) | Treatment of diabetes mellitus in adults | Green Specialist Initiation | May 2021(n) |
Interferon gamma-1b injection | For non-tuberculosis mycobacterial infection (Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned - see specialist advice) | Red | ICS APC November 2022 |
Intratect® | All indications | Red | |
Intravenous (IV) normal human immunoglobulins | All indications | Red | |
Ipilimumab 1mg/kg injection | For previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE TA716 | Red | ICS APC March 2022 (n) |
Ipilimumab solution | For malignant pleural mesothelioma | Red | ICS APC Chair's action January 2022. |
IQoro | For hiatus hernia | Do not prescribe/not yet classified | ICS APC November 2022 |
Irinotecan | Metastatic colorectal cancer used with 5-FU and folinic acid | Red | |
Iron sucrose | Iron deficiency anaemia requiring intravenous therapy | Red | |
Isavuconazole | Fungal infection (licensed indications) | Red | |
Isoniazid | Treatment of TB | Red | |
Isotretinoin | Oral retinoid - acne | Red | |
Itulazax 12 | For moderate to severe allergicrhinitis and/or conjunctivitis induced by pollen from the birch homologous group | Red | WY ICS APC 22nd June 2022 |
Ivabradine | For children with dilated cardiomyopathy and chronic heart failure (NYHA II to IV) with systolic dysfunction in sinus rhythm with elevated heart rate | Specialist Initiation | ICS APC September 2022 |
Ivabradine tablets | For the management of POTS (Postural tachycardia syndrome) and sinus tachycardia in patients with Long COVID | Specialist Recommendation | WY ICS APC 22nd June 2022 |
Ivabradine tablets | For heart failure in line with NICE TA267 | Specialist Recommendation | WY ICS APC 22nd June 2022 |
Ivabradine tablets | For angina in line with NICE CG126 | Green Restricted | WY ICS APC 22nd June 2022 |
Ivacaftor | For the use in the management of cystic fibrosis | Red | ICS APC November 2022 |
Ivacaftor/Elexacaftor/teacaftor (Symkevi®) | Cystic fibrosis (CF) patients | Red | ICS APC November 2022 |
Ivermectin cream | Rosacea | Green | |
Ivermectin (Tablets) | For the treatment of crusted scabies and topical treatment resistant scabies – Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC Sept 2023 |
IVF Treatment | All drugs | Red | |
Ixazomib | All indications | Red | |
Ixekizumab | Psoriatic arthritis in adult patients | Red | 31st July 2019 (n) |
Ixekizumab solution | For axial spondyloarthritis (licensed) | Red | ICS APC Chair's action January 2022. |
Japanese encephalitis | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Ketamine | All indications | Red | |
Ketogenic dietary products | For paediatric patients with epilepsy on a ketogenic diet and under the care of the regional service. See link to LTHT for additional information on ketogenic prescribable products | Green Specialist Initiation | |
Ketotifen | For all types of chronic allergic conjunctivitis requiring maintenance therapy. | Green | ICS APC September 2022 |
Kiovig® | All indications | Red | |
Lacosamide | Resistant partial seizures | Green Specialist Initiation | |
Lamivudine | Hepatitis B (commissioned by NHS England) | Red | |
Lamivudine | HIV infection (commissioned by NHS England) | Red | |
Lamivudine/abacavir/dolutegravir | HIV infection (commissioned by NHS England) | Red | |
Lamivudine/zidovudine | HIV infection (commissioned by NHS England) | Red | |
Lamivudine/zidovudine/abacavir | HIV infection (commissioned by NHS England) | Red | |
Lanadelumab | Hereditary angioedema | Red | |
Lanreotide | Neuroendocrine tumours, acromegaly | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Lanreotide | Red for NHS England indications | Red | |
Lanthanum | Control of hyperphosphataemia in patients with chronic renal failure | Amber | |
Lapatinib | Cancer | Red | |
Laronidase | Mucopolysaccharidosis | Red | |
Larotrectinib | For treating NTRK fusion-positive solid tumours NICE TA630 | Red | ICS APC November 2022 |
Latanaprost/netarsudil eye drops | For the reduction of elevated intraocular pressure (IOP) in adult patients with prmary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provided insufficient IOP reduction | Do not Prescribe/not yet classified | WY ICS APC Jan 2024 |
Ledipasvir/sofosbuvir | Hepatitis C (commissioned by NHS England) | Red | |
Leflunomide | Rheumatoid arthritis and psoriatic arthritis | *Please note: awaiting regional update of guidelines* Amber | Currently under RMOC consultation and will update accordingly - May 2021 |
Lenalidomide | All oncolocy indications | Red | WY ICS APC Jan 2024 |
Lenograstim | Recombinant human granulocyte - colony stimulating factor - neutropenia and Barth syndrome | Red | |
Lenvatinib (Kisplyx®) | For advanced renal cell carcinoma as per NICE TA858. Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. This is for this specific brand of Lenvatinib. Please note there is another brand classified for different indications | Red | WY ICS APC March 2023 (n) |
Lenvatinib (Lenvima®) | For differentiated thyroid carcinoma or hepatocellular carcinoma as per NICE TA858. Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. This is for this specific brand of Lenvatinib. Please note there is another brand classified for different indications. | Red | WY ICS APC March 2023 (n) |
Letermovir | Cytomegalovirus | Red | |
Letrozole | Advanced breast cancer - long term therapy | Green Specialist Initiation | |
Leuprorelin | Endometriosis or uterine fibroids | Amber - see GnRH analogues | |
Leuprorelin | Management of prostate cancer | Amber - see GnRH analogues | |
Levamisole | For paediatric nephrotic syndrome | Amber LHTH | |
Levamisole | For hookworm and roundworm | Red | 31.7.19 (n) |
Levetiracetam injection | For palliative care | Green Specialist Initiation | |
Levofloxacin (inhaled) | Cystic fibrosis (CF) | Red | |
Levonorgestrel | Contraception and treatment of heavy menstrual bleeding | Green | ICS APC September 2022 |
Lidocaine plasters for adults | Post herpetic neuralgia in adults | Black | |
Lidocaine plasters for 0-18 paediatrics | WY Lidocaine plasters for Paediatric 0-18 years | Specialist Initiation | Chair's action ICS APC June 2021 |
Lidocaine Oxide topical treatment | Haemmorrhoids | Do Not Prescribe | ICS APC November 2022 |
Lift® | Treatment of hypoglycaemia | Black - not yet classified | 27th November 2019 (n) |
Linezolid | Antibiotic - Microbiologist initiation only | Red | |
Linaclotide | Irritable Bowel Syndrome (IBS)NICE CG61 | Specialist Recommendation | ICS APC April 2022 |
Liothyronine and liothyronine with levothyroxine | Hypothyroidism | Amber WYH Commissioning Statement | |
Liothyronine and liothyronine with levothyroxine | Thyroid cancer | Red | |
Liothyronine and liothyronine with levothyroxine | For all other indications | Black | |
Lipegfilgrastim | Neutropenia | Red | |
Liposomal cytarabine-daunorubicin | Treatment of cancer (commissioned by NHS England) | Red | |
Liraglutide | Management of obesity | Red | |
Liraglutide | Type 2 diabetes (T2DM) | Green | |
Lisdexamfetamine | For attention-deficit hyperactivity disorder (ADHD) in adults only. | Amber | WY ICS APC July 2023 |
Lithium | Treatment and prophylaxis of mania, bipolar disorder and recurrent depression | Amber | WY ICS APC March 2023 |
Lithium carbonate | Motor neurone disease (MND) | Red | |
Lixisenatide | Type 2 diabetes (T2DM) | Green | |
Lomustine | Treatment of cancers | Red | |
Lomitapide | Homozygous familial hypercholesterolemia | Red | |
Lopinavir/ritonavir | HIV infection (commissioned by NHS England) | Red | |
Lorlatinib | Anaplastic lymphoma kinase (ALK) | Red | 29th July 2020 (n) |
Loteprednol | Peri-operative use | Red | |
Loteprednol | Glaucoma | Green Specialist Initiation | |
Low-molecular Weight heparin (Enoxaparin, Dalteparin and Tinzaparin) | Urgent bridging of patients on warfarin (for VTE or heart valve), with significantly sub-therapeutic INR, in accordance with provider dosing guidance (taking account of patient weight and renal function). | Specialist Recommendation | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Enoxaparin, Dalteparin and Tinzaparin) | For pre-procedural bridging therapy for patients usually on warfarin (as directed by surgeon/clinical haematologist). | Specialist Recommendation | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Enoxaparin, Dalteparin and Tinzaparin) | Treatment of acute VTE and maintenance during pregnancy. | Specialist Initiation | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Enoxaparin, Dalteparin and Tinzaparin) | For prophylaxis in obstetric patients. | Specialist Initiation | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Dalteparin, Enoxaparn and Tinzaparin) | Extended post-operative thromboprophylaxis. | Red | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Dalteparin, Enoxaparn and Tinzaparin) | High risk patients with plaster cast (about 6 weeks whilst immobile) – off-label. | Red | WY ICS APC 24th May 2023 |
Low-molecular Weight heparin (Dalteparin, Enoxaparn and Tinzaparin) | Postpartum thromboprophylaxis in high risk women (7 days or 6 weeks) | Red | WY ICS APC 24th May 2023 |
Low -molecular Weight heparin (Dalteparin, Enoxaparin and Tinzaparin) | Treatment of VTE in patients with DVT or PE or other conditions where anticoagulation is required and other treatments are not suitable. | Amber | |
Low-molecular Weight heparin (Dalteparin, Enoxaparin and Tinzaparin) | Extended treatment & prophylaxis of VTE in adult patients with solid tumours | Amber | |
Lumacaftor/ivacaftor | Cystic fibrosis (CF) | Red | |
Lumasiran | For treating primary hyperoxaluria type 1. | Red | WY ICS APC Nov 2023 |
Lurasidone | Schizophrenia (adults) | Green Specialist Initiation | |
Lusutromopag | For treating severe thrombocytopenia in adults ith chronicliver disease having planned invasive procedures NICE TA617 | Red | ICS APC April 2022 |
Lutetium (177lu) oxodotreotide | Treatment of cancer (commissioned by NHS England) | Red | |
Lutein and antioxidants | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Macitentan | Pulmonary arterial hypertension | Red | |
Mannitol dry powder inhaler | Treatment of cystic fibrosis | Red | |
Mavacamten | For treating symptomatic obstructive hypertrophic cardiomyopathy NICE TA913 | Red | WY ICS APC Nov 2023 |
Maraviroc | HIV infection (commissioned by NHS England) | Red | |
Maribavir | Indicated for the treatment of cytomegalovirus (CMV) infection after transplant as per NICE TA860. Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC March 2023 (n) |
Maviret® | Hepatitis C (Commissioned by NHS England | Red | |
Mecasermin | Growth failure | Red | |
Medtronic Guardian 4 | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Medtronic Smart MDI | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Melatonin MR | Work is on-going on classification and transfer of care document | Amber. Shared care guideline Commissioning statement How to crush tablets Crushing | 11th October 2022 (a) |
Melatonin MR | Cerebral palsy | Green Specialist Initiation Commissioning statement How to crush tablets Crushing | 11th October 2022 (a) |
Melatonin 1mg/ml oral solution | Jet lag in adults | Black | 31st July 2019 (n) |
Melphalan | Treatment of cancers | Red | |
Memantine | Moderately severe to severe Alzheimers disease. | Green Specialist Initiation | |
Meningitis ACWY vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Mepacrine | Malaria | Red | 22nd January 2020 |
Mepacrine | Treatment of Systemic Lupus Erythematosus and dermatological conditions in Adults | Amber LTHT guidance for information | May 2021 (a) |
Mepolizumab | Asthma | Red | |
Mercaptamine hydrochloride viscous eyedrops | For corneal cystine deposits in people aged 2 years and over | Red | ICS APC Chair's action January 2022. |
Mercaptopurine | Gastroenterology | SWYAPC | 30th September 2020 (a) |
Mercaptopurine | For the treatment of Inflammatory Bowel Disease in Children | Amber | |
Mercaptopurine | Treatment of cancers | Red | |
Meropenem | For use as recommended by local antimicrobial guidance or by microbiology. | Red | WY ICS APC Jan 2024 |
Meropenem-varbobsctam IV injection | For klebsiella pneumoniae carbapenemase producint carbapenem-resistant Enterobacteriacease or when high suspicion of this | Red | ICS APC April 2022 |
Mesalazine | For the treatment of ulcerative colitis and Crohn's disease and other types of inflammatory bowel disease. | Specialist Initiation | WY ICS APC Nov 2023 |
Metaraminol solution | Indicated for the treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaethesia and as an adjunct to accepted remedial procedures. | Red | 22nd September 2021 (n) |
Methenamine | Lower UTI Prophylaxis in adult women | Green Restricted | ICS APC November 2022 |
Methotrexate (oral, IM & SC) | Cancer indications | Red | |
Methotrexate (IM and SC) | Non-cancer indications | Red | |
Methotrexate S/C | Alone or with corticosteriods for mild to moderate Crohn's disease in patients refractory to thiopurines. | Red | ICS APC November 2022 |
Methotrexate (oral) | Licensed indications – Rheumatoid arthritis, Psoriatic arthritis Off-label indication - Other inflammatory arthritides, connective tissue disease (not for cancer or dermatological conditions) | LTHT guidance | Currently under RMOC consultation and will update accordingly - May 2021 |
Methotrexate (oral) | Licensed indication: severe uncontrolled psoriasis. Off-label conditions: e.g pemphigoid, pemphigus, sarcoidosis, scleroderma, dermatomyositis, eczema. See shared care guideline for further indications | Amber | |
Methotrexate (oral) | Non cancer indications in paediatrics | Amber | |
Methoxyflurane inhalation vapour | Anaesthetic | Red | WY ICS APC July 2023. |
Methylnaltrexone subcutaneous injection | Severe opioid induced constipation | Black | |
Methylphenidate | For ADHD in school-age children, adolescents and adults | Amber | |
Metolazone | For treatment of oedema related to kidney disease and heart failure and for mild/moderate hypertension along or in combination with other antihypertensive medicines | Specialist Recommendation | ICS APC November 2022 |
Metyrapone | Management of patients with Cushing’s Syndrome | Red for new patients Green Specialist Initiation for existing patients | |
Mexiletine | Non-dystrophic myotonia (commissioned by NHS England) | Red | |
Mexiletine | For treating life-threatening ventricular arrhythmias | Red | WY ICS APC Nov 2023 |
Mianserin | For treating depression | Specialist Recommendation | WY ICS APC Jan 2024 |
Micafungin | Fungal infections | Red | |
Miconazole buccal | Oropharyngeal candidiasis | Green Specialist Initiation | |
Micronised progesterone (Oral) | With oestrogen in post-menopausal women with an intact uterus, as HRT | Green | WY ICS APC 22nd June 2022 |
Midazolam oromucosal solution | Convulsive seizures | Green Specialist Initiation | |
Midodrine | For postural hypertension, vasovagal syncope, or severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other treatments are inadequate. | Specialist Recommendation | WY ICS APC 24th May 2023 |
Midostaurin | Treatment of cancers (commissioned by NHS England) | Red | |
Midostaurin | For untreated acute myeloid leukaemia NICE TA523 | Red | ICS APC November 2022 |
Migalastat | Fabry's disease | Red | |
Miglustat | Gaucher's disease/Niemann-Pick disease | Red | |
Miglustat | For treating late-onset Pompe disease (with cipaglucosidase alfa) NICE TA912 | Red | WY ICS APC Nov 2023 |
Minocycline for acne | Treatment of acne for new patients | Black | 28th July 2021 (a) |
Minocycline for acne | Treatment of acne for existing patients (with prescribers considering deprescribing in all patients where appropriate | Green | 28th July 2021 (n) |
Minoxidil (all topical preparations) | For the treatment of male and female pattern baldness | Do not prescribe | ICS APC November 2022 |
Minoxidil | Treating severe hypertension, in additional to a diuretic and a betablocker | Specialist Recommendation | ICS APC November 2022 |
Mirabegron | Overactive bladder syndrome | Green | |
Mirikizumab | For treating moderately to severely active ulcerative colitis | Red | WY ICS APC Jan 2024 |
Mirtazapine | For treating depression | Green | WY ICS APC Jan 2024 |
Mitomycin C injection | For dacryocystorhinostomy (Treatment for a blocked tear duct) | Red | ICS APC April 2022 |
Mitotane | Treatment of cancers | Red | |
Mobocertinib | For the treatment of adult patients with epidermal growth factor receptor exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer who have received prior platinum based chemotherapy as per NICE TA855. | Red | WY ICS APC March 2023 (n) |
Moclobemide | For treating depression and anxiety | Specialist Initiation | WY ICS APC Jan 2024 |
Modafinil | Treatment of Adults with – Narcolepsy, Fatigue in patients with MS, Residual sleepiness associated with Obstructive Sleep Apnoea and Idiopathic Hyper-somnolence | Amber LTHT guidance for information | May 2021 (a) |
Mogamulizumab | For previously treated mycosis fungoides and Sezary Syndrome - NICE TA754 | Red | WY ICS APC 22nd June 2022 |
Molnupiravir | Antiviral medication that inhibits the replication of certain RNA viruses, and is used to treat COVID-19 in those infected by SARS-CoV-2 | Red | ICS APC Chair's action January 2022. |
Mosunetuzumab | For treating relapsed or refractory follicular lymphoma NICE TA892 | Do Not Prescribe | WY ICS APC Nov 2023 |
Mycophenolate | Off-label indications –systemic lupus erythematosus (SLE), particularly lupus nephritis, other connective tissue diseases and systemic vasculitis. Treatment of myasthenia gravis in patients intolerant or non-responding to azathioprine | *Please note: awaiting regional update of guidelines* Amber | Currently under RMOC consultation and will update accordingly - May 2021 |
Mycophenolate | Cytotoxic immunosuppressant - prophylaxis of acute transplant rejection | Amber | |
Mycophenolate | Indications not classified as amber | Red | |
Mycophenolate | Paediatric rheumatology | Amber | Currently under RMOC consultation and will update accordingly - July 2021 |
Mycophenolate | For the prevention of relapse in frequently relapsing nephrotic syndrome in paediatrics | Amber | Currently under RMOC consultation and will update accordingly - July 2021 |
Mydrane | As drug to dilate pupil and also prevent pupil becoming small during Cataract surgery | Red | 22nd January 2020 |
Mysimba® (naltrexone plus bupropion) | For the treatment of overweight and obesity | Black | |
Nabilone | Antiemetic; Multiple sclerosis treatment | Red | |
Nafarelin | IVF - gonadorelin analogue | Red | |
Nalmefene (only for patients under the care of alcohol services including shared care) | Alcohol dependence | Red | |
Naloxegol | For opioid-induced constipation according to NICE TA345 | Green Restricted | ICS APC November 2022 |
Naloxone hydrochloride injection | For pruritus in liver disease - licensed for opioid overdose | Red | ICS APC Chair's action January 2022. |
Naltrexone | Maintain abstinence in alcohol-dependent patients | Naltrexone | March 2021 (a) |
Naltrexone | For pruritus in liver disease | Specialist Initiation | ICS APC April 2022 |
Naltrexone | Hailey-Hailey disease | Red | 20th September 2019 (n) |
Nasal sprays available over-the-counter for symptomatic relief of hay fever and congestion | For the treatment of mild to moderate hay fever/seasonal rhinitis | Black | 28th July 2021 (a) |
Natalizumab | Multiple sclerosis (MS) | Red | |
Natalizumab SC injection | In pre-filled syringes for multiple sclerosis NICE TA127 | Red | ICS APC April 2022 |
Natamycin eye drops | Treatment of keratitis due to a mould | Red | 29th July 2020 (n) |
Needles for pre-filled and reusable Insulin pens | For needles costing more than £5 per 100 | Black NHSE items that should not be routinely prescribed in Primary Care | |
Nefopam | Pain | Black for new patients unless initiated and successfully trialled under the care of a pain specialist as per SWYAPC nefopam commissioning statement | 10th September 2020 |
Neilmed (purified sea water) | Nsal rinse for postnasal surgery and endonasal pituitary surgery | Red | WY ICS APC Nov 2023 |
Nelarabine | Treatment of cancers | Red | |
Nelfinavir | HIV infection (commissioned by NHS England) | Red | |
Neomycin oral tablet | Surgical prophylaxis alongside oral metronidazole, plus standard intravenous surgical prophylaxis for colorectal surgery – with mechanical bowel preparation | Red | |
Neonatal Probiotics | To aid reduction in risk of necrotising enterocolitis. | Red | WY ICS APC July 2023. |
Nephro-vite® | Vitamin supplementation in renal impairment | Green Specialist Initiation | |
Neratinib | Breast Cancer | Red | 27th November 2019 (n) |
Netilmicin/dexamethasone eye drops | Indicated for the treatment of inflammatory ocular conditions of the anterior segment of the eye, including post-operative cases, where bacterial infection or a risk of bacterial infection with netilmicin-susceptible micro organisms exists | Do not prescribe/not yet classified | WY ICS APC 22nd June 2022 |
Netupitant and palonosetron | Anti-emetic for use with cancer chemotherapy | Red | |
Neuropad | For detecting preclinical diabetic peripheral neuropathy | Do not prescribe | ICS APC November 2022 |
Nevirapine | HIV infection (commissioned by NHS England) | Red | |
Nilaqua | Waterless bathing product | Do not prescribe/not yet classified | ICS APC November 2022 |
Nilotinib | Treatment of cancers | Red | |
Nintedanib | Treatment of cancers; idiopathic pulmonary fibrosis | Red | |
Nintedanib | Treatment of other chronic fibrosing interstitial lung diseases (ILDS) with a progressive phenotype (adults) NICE TA747 | Red | ICS APC April 2022 |
Nintedanib (oral) | For treating progressive fibrosing interstitial lung disease | Red | WY ICS APC 22nd June 2022 |
Niraparib | Treatment of cancers | Red | |
Nirmatrelvir/Ritonavir | For COVID-19 in adults not requiring oxygen who are at increased risk of severe disease | Red | ICS APC April 2022 |
Nitazoxanide | Unlicensed in UK - for treatment of Cryptosporidiosis and Giardiasis | Red | |
Nitisinone | Alkaptonuria; tyrosinaemia | Red | |
Nitric oxide | For treating pulmonary arterial hypertension | Red | WY ICS APC 24th May 2023 |
Nivolumab | Treatment of cancers NICE TA780, 746,736,724,716,713,707 | Red | ICS APC September 2022 |
Nivolumab | For recurrent or metastatic squamous cell carcinoma of head and neck after platinum-based chemotherapy. For adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. | Red | ICS APC April 2022 |
Nivolumab solution | For malignant pleural mesothelioma | Red | ICS APC Chair's action January 2022. |
Nivolumab 3mg/kg injection | For previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE TA716 | Red | ICS APC March 2022 (n) |
Nonacog beta pegol | Haemophilia B | Red | |
Non-nucleoside reverse transcriptase inhibitors | HIV infection (commissioned by NHS England) | Red | |
Norethisterone 5mg tablets | For the postponement of menstruation | Green | WY ICS APC Nov 2023 |
Normal immunoglobulin | All indications | Red | |
Nucleoside reverse transcriptase inhibitors (nucleoside analogues) | HIV infection (commissioned by NHS England) | Red | |
Nusinersen intrathecal injection | Spinal muscular atrophy (commissioned by NHS England) | Red | |
Obeticholic acid | Primary biliary cirrhosis | Red | |
Obinutuzumab | Treatment of cancers | Red | |
Ocrelizumab | Multiple sclerosis (MS) | Red | |
Ocriplasmin | Retinal disorders | Red | |
Octagam® | All indications | Red | |
Octreotide | For post operative chylothorax in paediatric cardiothoracic patients | Red | WY ICS APC 24th May 2023 |
Octreotide | For palliative care indications | Green Specialist Initiation | |
Octreotide | Amber for licensed CCG funded indications (symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas, acromegaly, prevention of complications after pancreatic surgery). Red for NHS England indications | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. Red for NHS England indications | |
Octreotide (off-label indications) | Off-label indications | Red | |
Odevixibat sesquihydrate | Indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. | Red | ICS APC September 2022 |
Ofatumumab injection | For relapsing multiple sclerosis | Red | ICS APC 20th October 2021 (n) |
Olanzapine (IM injection) | Atypical antipsychotic - schizophrenia and bipolar disorders | Red | |
Olanzapine (oral) | Atypical antipsychotic - schizophrenia and bipolar disorders | Green Specialist Initiation | |
Olaparib | Treatment of cancers | Red | |
Olaparib | For the maintenance treatment of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. | Red | 22nd September 2021(n) |
Olopatadine/mometasone nasal spray | Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis | Green | ICS APC Chair's action January 2022. |
Omalizumab | For all indications | Red | WY ICS APC Nov 2023 (a) |
Ombitasvir/paritaprevir/ritonavir | Hepatitis C (commissioned by NHS England) | Red | |
Omega 3 and other fish oils | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Opicapone | For Parkinson's disease | Green Specialist Initiation | |
Oral rehydration solution | Short bowel patients | Specialist Initiation | ICS APC November 2022 |
Oral immunotherapy (Acarizax, Grazax and Itulazax) | For the treatment of allergen specific fhinitis and conjunctivitis in adult and paediatric services | Specialist Initiation with additional guidance | WY ICS APC Jan 2024 |
Oraldene® gel and mouthwash | Oral hygeine | Red | |
Osimertinib | Treatment of cancers | Red | |
Osimertinib | Adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations NICE TA761 | Red | ICS APC April 2022 |
Ospemifene 60mg tablet | For moderate-severe vulvar and vaginal atrophy in postmenopausal women who are not candidates for vaginal oestrogen therapy or who cannot administer vaginal oestrogen. | Green Restricted | WY ICS APC March 2023 (n) |
Oxaliplatin | Metastatic colorectal cancer used with 5-FU and folinic acid | Red | |
Oxandrolone | Treatment of hypermetabolism in burns patients | Red | 29th July 2020 (n) |
Oxcarbazepine | Epilepsy | Green Specialist Initiation | |
Oxcarbazepine | For the treatment of trigeminal neuralgia and 2nd line after carbamazepine | Specialist Initiation | WY ICS APC 24th May 2023 |
Oxybutynin | For nocturnal enuresis in children | Specialist Recommendation | WY ICS APC Jan 2024 |
Oxycodone and naloxone MR | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Ozanimod | Recommended as an option for treating moderately to severely active ulcerative colitis in adults as per NICE TA828 | Red | ICS APC November 2022 |
Ozanimod hydrochloride | Multiple sclerosis (MS) | Do not prescribe | ICS APC October 2021 |
Palbociclib | Cancer | Red | |
Paliperidone depot 6 monthly | For use as an antipsychotic in the treatment of schizophrenia. Please be aware this medicine classification is dependent on the product | Red | WY ICS APC March 2023 (a) |
Palivizumab | Prophylaxis of respiratory syncytial virus (RSV) | Red | |
Pancreatin preparations | Pancreatic insufficiency | Specialist Recommendation | ICS APC November 2022 |
Panitumumab | Treatment of cancers | Red | |
Panobinostat | Treatment of cancers | Red | |
Para-aminosalicylic acid | TB | Red | |
Paracetamol and tramadol | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Parathyroid hormone | Specialist endocrinology conditions | Red | |
Paravit CF Capsules | Cystic Fibrosis | Green Specialist Initiation | 27th November 2019 (n) |
Paravit CF Capsules | Cholestatic liver disease | Green Specialist Initiation | 27th November 2019 (n) |
Paricalcitol | Hyperparathyroidism (commissioned by NHS England) | Red | |
Paritaprevir | Hepatitis C (commissioned by NHS England) | Red | |
Pasireotide | Cushing's disease | Red | |
Patiromer | For acute management hyperkalaemia as per NICE TA623 | Red | WY ICS APC 24th May 2023 |
Patiromer | Longer term use for hyperkalaemia in dialysis patients, struggling to adhere to dietary restrictions or who remain hyperkalaemic despite dietary restrictions. Note as patients attend dialysis units bloods will be taken and monitored by Secondary Care. | Specialist Initiation | WY ICS APC 24th May 2023 |
Patisiran | Amyloidosis (commissioned by NHS England) | Red | |
Paxlovid | An antiviral medicine used for treating mild-to-moderate COVID | Red | ICS APC Chair's action 16th February 2022 |
Pazopanib | Treatment of cancers | Red | |
Pegaspargase | Treatment of cancers | Red | |
Pegcetacloplan | For paroxysmal nocturnal haemoglobinuria NICE TA778 | Red | ICS APC September 2022 |
Pegylated liposomal doxorubicin | Treatment of cancers | Red | |
Peg-filgrastim | Reduction in neutropenia with cytotoxic chemotherapy | Red | |
Peg-interferon alfa | Treatment of hepatitis B and C | Red | |
Peginterferon beta-1a | Multiple sclerosis (MS) | Red | |
Pegunigalsidase alfa | For treating Fabry disease NICE TA915 | Red | WY ICS APC Nov 2023 |
Pegvisomant | Acromegaly | Red | |
Pembrolizumab | Treatments of Cancer | Red | |
Pembrolizumab | For the first line treatment of squamous non-small cell lung cancer in combination with carboplatin and paclitaxel | Red | ICS APC September 2022 |
Pembrolizumab | For untreated advanced oseophageal and gastro-oesophageal junction cancer. For treating relapsed or refractory classical Hodgkin lymphoma in people added 3 and older NICETA772 | Red | ICS APC April 2022 |
Pembrolizumab | For oncology indications | Red | WY ICS APC Jan 2024 |
Pembrolizumab solution for infusion | For untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | Red | ICS APC Chair's action January 2022. |
Pemetrexed | Treatment of cancers | Red | |
Pemigatinib | For cholangiocarcinoma with FGFR2 fusion or rearrangement NICE TA722 | Red | ICS APC April 2022 |
Pentosan polysulphate | Interstitial Cystitis | Red | January 2020 (removing unlicensed) |
Penicillamine | For rheumatoid arthritis – 12-month extension of the SWY guidance approved to be used by Bradford & Craven/Calderdale/Kirklees and Wakefield until a full review can take place. | Penicillamine | WY ICS APC Sept 2023 |
Pentoxifylline | For treating venous leg ulceration. Continue treatment until ulcer heals but review on a monthly basis | Specialist Recommendation Restricted | WY ICS APC March 2023 (n) |
Pentoxifylline | For intermittent claudication in peripheral arterial disease (Not recommended by NICE TA223) | Do not prescribe | WY ICS APC 24th May 2023 |
Perampanel | Epilepsy | Green Specialist Initiation | |
Perindopril arginine | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Pertuzumab | Treatment of cancers | Red | |
Phenazone/lidocaine hydrochloride ear drops (Otigo) | For local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation Otitis media (acute) antimicrobial prescribing NICE guidance | Green | WY ICS APC March 2023 (n) |
Phenelzine | For depressed patients clinically characterised as 'atypical', 'non endogenous', 'neurotic' or where treatment with other antidepressants has failed in adult services. | Specialist Initiation guidance | WY ICS APC July 2023. |
Phenol 2% in Zinc paste | Intractable pruritus ani | Red | |
Phenylbutazone | NSAID - ankylosing spondylitis | Red | |
Phenylephrine/tropicamide ophthalmic insert (Mydriasert®) | Surgical mydriasis | Red | |
Pholcodine containing Medicinal products | For treating coughs and colds. Discontinued. | Do not prescribe | WY ICS APC 24th May 2023 |
Phytomenadione capsules | Not licensed in UK | Green Specialist Initiation | |
Pimecrolimus (topical) | For the treatment of oral lichplanus and similar immune-inflammatory oral mucosal disease (off license) | Specialist Recommendation | ICS APC September 2022 |
Pirenzepine | For clozapine-induced hypersalivation | Red | WY ICS APC Jan 2024 |
Pirfenidone | Antifibrotic for idiopathic pulmonary fibrosis | Red | |
Pitolisant | For treating narcolepsy with or without cataplexy (initiated by a specialist). This drug is also classified at Do Not Prescribe for sleep apnoea | Red | WY ICS APC Nov 2023 |
Pitolisant | For treating sleep apnoea. This drug is also classified as red for narcolepsy with or without cataplexy. | Do Not Prescribe | WY ICS APC Nov 2023 |
Pivmecillinam | Urinary tract infections | Green | |
Pixantrone | Treatment of cancers | Red | |
Bowel preparation products | Indicated in adults for bowel cleansing prior to procedure | Red | 28th July 2021 (n). 2nd November 2022 changed from Plenvu to bowel preparation products |
Plerixafor | Stem cell mobilisation | Red | |
Polatuzumab | Treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant | Red | 24th March 2021(n) |
Pomalidomide | Treatment of cancers. Myelofibrosis | Red | |
Ponatinib | Treatment of cancers | Red | |
Ponesimod f/c tablets (initiation and maintenance packs) | Treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features NICE TA767 | Red | ICS APC March 2022 (n) |
Poractant alfa | For treating respiratory distress syndrome. | Red | WY ICS APC Nov 2023 (a) |
Posaconazole | All indications | Red | |
Potassium Citrate tablets | For renal and ureteric stones (ULM) in adults and children | Red | ICS APC 20th October 2021 (n) |
Potassium iodide | For treatment of erythema nodosum | Red | |
Pralsetinib | For RET+ve NSCLC - NICE TA812 does not recommend for this indication | Do not prescribe | ICS APC November 2022 |
Pramipexole standard release tablet | Restless legs syndrome | Green | ICS APC November 2022 |
Pramipexole standard release tablets | For Parkinson's disease | Specialist Recommendation | ICS APC November 2022 |
Pramipexole MR tablets | Parkinson's disease | Specialist Recommendation | WY ICS APC 22nd June 2022 |
Prasterone pessaries | For treating vulvar and vaginal atrophy in line with NICE | Green Restricted | WY ICS APC Jan 2024 |
Prasugrel | Cobination with aspirin for the prevention of atherothrombotic events in patients with acute coronory syndrome undergoing percutaneous coronary intervention | Green Specialist Initiation | |
Prasugrel | For the treatment of patients with intracranial stents | Specialist Initiation | WY ICS APC Nov 2023 (a) |
Prednisolone enema/suppositories | Ulcerative colitis | Specialist Recommendation | ICS APC November 2022 |
Prednisone MR | Rheumatoid arthritis (RA) | Black | |
Pre-exposure prophylaxis (PrEP) | For prevention of HIV in adults. Only as part of a clinical trial. Further details from NHS England who commission this | Black | |
Pretomanid | Multi-drug resitant TB | Red | |
Privagen® | All indications | Red | |
Probiotics | All indications | Black Conditions for which over the counter items should not routinely be prescribed | |
Procarbazine | Treatment of cancers | Red | |
Progesterone (micronised) vaginal | For treatment of threatened miscarriage | Specialist Initiation | ICS APC September 2022 |
Propantheline | Hypersalivation | Specialist Recommendation | ICS APC November 2022 |
Propranolol | Paediatric Migraine | Green Specialist Initiation See LTHT guidance for information | |
Protease inhibitors | HIV infection (commissioned by NHS England) | Red | |
Protein C | As per BCSH guidelines for specialised indications | Red | |
Protein kinase inhibitors | Endocrinology; non-malignant conditions | Red | |
Prothrombin complex | As per BCSH guidelines for specialised indications | Red | |
Prucalopride | For use with Colon Capsule Endoscopy | Red | ICS APC November 2022 |
Prucalopride | Chronic constipation in women when other laxatives fail to provide an adequate response - NICE TA211 | Specialist Recommendation | ICS APC November 2022 |
Prucalopride | For use as a prokinetic in paediatric patients with intestinal pseudo obstruction | Specialist Initiation | WY ICS APC Jan 2024 |
Pyrazinamide | Treatment of TB | Red | |
Pyridoxine (Xonvea®) | Nausea and vomiting in pregnancy | Black not yet classified | |
Quetiapine | Atypical antipsychotic - schizophrenia | Green Specialist Initiation | |
Quinidine | Short QT syndrome, Brugada syndrome, and idiopathic ventricular fibrillation (VF) | Red | WY ICS APC 24th May 2023 |
Quinidine sulphate tablets | Ventricular arrhythmia | Red | 31st July 2019 (n) |
Rabies vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Radium-223 dichloride | Treatment of cancers | Red | |
Raltegravir | HIV infection (commissioned by NHS England) | Red | |
Raltitrexed | Advanced colorectal cancer | Red | |
Ranibizumab | All indications | Red | |
Ranolazine | Not for routine use as an antianginal agent. It is used as an add-on for symptomatic treatment of stable angina pectoris inadequately controlled or intolerant to other antianginal therapeutics NICE CG126 | Specialist Recommendation Restricted | WY ICS APC 24th May 2023 |
Rasagiline | Parkinson's disease | Green Specialist Initiation | |
Rasburicase | Hyperuricaemia | Red | |
Ravulizumab | Paroxysmal nocturnal haemoglobinuria (commissioned by NHS England) | Red | |
Ravulizumab infusion | For treating atypical haemolytic uraemic syndrome | Red | ICS APC Chair's action January 2022. |
Regorafenib | Treatment of cancers | Red | |
Relugolix/estradiol/norethisterone (Ryeqo) | For treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age as per NICE TA832. | Specialist Recommendation | ICS APC November 2022 |
Remdesivir | Treatment for SARS-CoV-2 infection | Red | 29th July 2020 (n) |
Renavit® | Vitamin supplementation in renal impairment | Green Specialist Initiation | |
Reslizumab | Asthma | Red | |
Ribavirin | Hepatitis C (commissioned by NHS England) | Red | |
Ribociclib | Cancer | Red | |
Ribociclib tablets | For breast cancer | Red | ICS APC Chair's action January 2022. |
Rifabutin | For treating pulmonary tuberculosis – Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice. | Red | WY ICS APC Sept 2023 |
Rifampicin | Treatment of TB | Red | |
Rifampicin | For pruritus in liver disease - unlicensed for use in children for pruritus. | Specialist InitiationLTHT guidance | ICS APC April 2022 |
Rifampicin | Treatment of Folliculitis Decalvans, Acne Keloidalis & Hidradenitis Suppurativa in Adults | Green Specialist Initiation | May 2021 (n) |
Rifater® (rifampicin/isoniazid/pyrazinamide ) | Treatment of TB | Red | |
Rifaximin | Treatment of small intestinal bacterial overgrowth and for the treatment of chronic refractory pouchitis | Red | |
Rifaximin | Prevention of hepatic encephalopathy in adult patients | Green Specialist Initiation | |
Rifinah® (rifampicin/isoniazid) | Treatment of TB | Red | |
Rilpivirine | HIV infection (commissioned by NHS England) | Red | |
Riluzole | To extend life or time to mechanical ventilation for patients with amyotrophic lateral sclerosis | Amber LTHT guidance | March 2020 (a) Currently under RMOC consultation and will update accordingly - July 2021 |
Rimegepant (Prevention) Vydura® | For preventative treatment of episodic migraine in adults in line with NICE TA906. Patients transferred after a minimum of 12 weeks. | Specialist Initiation | WY ICS APC Sept 2023 |
Rimegepant (Treatment) Vydura | For acute treatment of migraine with or without aura | Specialist Initiation | WY ICS APC Jan 2024 interim classification |
Riociguat | Pulmonary arterial hypertension (CTEPH). Pulmonary arterial hypertension | Red | |
Ripretinib | For treating advanced gastrointestinal stromal tumours after 3 or more therapies NICE TA881 | Do Not Prescribe | WY ICS APC Nov 2023 |
Risankizumab | Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. | Red | 22nd September 2021 (n) |
Risankizumab | Management of moderate to severe Crohn's disease in people aged >16 years with an inadequate response or intolerance to conventional or biologic therapy (licence extension) ID3986 GID-TA10884) | Red | ICS APC September 2022 |
Risdiplam | Spinal muscular atrophy | Red | 4th Sept 2020 |
Risperidone injection | Schizophrenia and other psychoses in patients tolerant to risperidone by mouth | Red | |
Risperidone oral | Atypical antipsychotic - schizophrenia | Green Specialist Initiation | |
Ritonavir | HIV infection (commissioned by NHS England) | Red | |
Ritonavir/lopinavir | HIV infection (commissioned by NHS England) | Red | |
Rituximab | All uses | Red | |
Rivaroxaban | See DOACs | See DOACs | |
Rivaroxaban | For preventing atherothrombotic events in people with coronary or peripheral artery disease when taken in combination with aspirin as per NICE TA607 | Green Restricted | ICS APC November 2022 |
Rivaroxaban | For the prevention of venous thrombo-embolism (VTE) in patients with myeloma (ULM) | Red | WY ICS APC Nov 2023 |
Rivastigmine | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation | |
Rivastigmine patches | Mild to moderate dementai in patients with swallowing difficulties | Green Specialist Initiation | |
Roflumilast | As per TA461: Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if: •the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and •the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid | Green Specialist Initiation | |
Romiplostim | Immune (idiopathic) thrombocytopenia | Red | |
Romosozumab | Treating of severe osteoporosis - NICE TA791 | Red | Chair's Action 25th August 2022 |
Ropinirole | For Parkinson’s disease. Please note this medicine is also classified for the treatment of restless leg syndrome (see separate entry Green Restricted). | Specialist Recommendation | WY ICS APC March 2023 (a) |
Ropinirole | For treatment of restless legs syndrome. Restricted in line with the CKS guidance for restless leg syndrome. Please note this medicine is also classified for the treatment of Parkinson’s disease (see separate entry Specialist Recommendation) | Green Restricted | WY ICS APC March 2023 (n) |
Rotigotine transdermal patches | Parkinson's disease, either used alone or as an adjunct to levodopa with dopa-decarboxylase inhibitor | Green Specialist Initiation | |
Roxadustat | Indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease NICE TA807 | Red | WY ICS APC November 2022 |
Rubefacients (excluding topical NSAIDs) | All indications | Black NHSE items that should not be routinely prescribed in Primary Care | |
Rucaparib | Treatment of cancers | Red | 18th March 2020 (n) |
Rufinimide | Epilepsy | Green Specialist Inititation | |
Rupatadine fumarate | For treating chronic urticaria/angioedema | Secialist Initiation with additional guidance LTHT guidance | |
Ruxolitinib | Treatment of cancers | Red | |
Sacubitril valsartan | According to NICE TA388 for treating symptomatic chronic heart failure with reduced ejection fraction | Green Specialist Initiation | |
Sacituzumab govitecan 180mg solution for infusion | Licensed for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer | Red | WY ICS APC March 2022 (n) |
Safinamide | Parkinson's disease, as an adjunct to levodopa alone or in combination with other antiparkinsonian drugs, for mid- to late-stage fluctuations | Green Specialist Initiation | |
Sapropterin | For children with phenylketonuria. Maternal phenylketonuria (NHS England) | Red | |
Saquinavir | HIV infection (commissioned by NHS England) | Red | |
Sarilumab | Paediatric indications (where adult NICE TAs are available) | Red | |
Sarilumab | For moderate to severe active rheumatoid arthritis in adults according to NICE TA485 | Red | |
Sativex® Spray (cannabis-based product. | Treatment of spasticity in patients with MS | Black not yet classified. For further information see West Yorkshire Health and Care Partnership WY Partnershipwebsite | 28th July 2021 (a) |
Saxagliptin | Type 2 diabetes (T2DM) | Green | |
Sebelipase alfa | Lysosomal acid lipase deficiency | Red | |
Secukinumab | Licensed for the treatment of active non-radiographic axial spondylarthritis with objective signs of inflammation. NICE TA719 | Red | WY ICS APC March 2022 (n) |
Secukinumab | For severe plaque psoriasis in children and young people NICE TA734 | Red | WY ICS APC April 2022 |
Secukinumab | For all indications | Red | WY ICS APC Jan 2024 |
Selexipag | Pulmonary arterial hypertension | Red | |
Selpercatinib hard capsules (40mg & 80mg) | Treatment of adults with advanced RET fusion-positive non-small cell lung cancer NICE TA760 Treatment of adults and adolescents aged ≥12 years with advanced RET-mutant medullary thyroid cancer NICE TA742 | Red | WY ICS APC March 2022 (n) |
Selpercatinib | For treating advanced thyroid cancer with RET alterations. For previously treated RET fusion-positive advanced non-small-cell lung cancer NICE TA742 | Red | WY ICS APC April 2022 |
Selumetinib | For the treatment of symptomatic inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 aged 3 years and above in line with HST20. | Red | WY ICS APC November 2022 |
Semaglutide (Wegovy) | WY Partnership For managing overweight and obesity as per NICE TA875. This is an interim holding position awaiting further discussions on how NICE TA875 will be implemented across West Yorkshire. | Do not prescribe/not yet classified. | WY ICS APC March 2023 (a) |
Semaglutide Oral | Treatment of adults with insufficiently controlled T2DM, according to NICE guidelines (NG28) | Green | 24th March 2021 (n) |
Sertraline | For pruritus in liver disease | Specialist Recommendation | WY ICS APC April 2022 |
Sevelamer | Hyperphosphataemia in chronic kidney disease patients who may also be on haemodialysis or peritoneal dialysis | Amber | |
Sildenafil | Post prostatectomy or radiotherapy | Green Specialist Initiation | |
Sildenafil | Raynaud's phenomenon and digital ulceration associated with connective tissue disease | Green Specialist Initiation | May 2021 (a) |
Sildenafil | For treating pulmonary hypertension in adults and paediatrics | Red | WY ICS APC 24th May 2023 |
Silicone scar gels and sheets | When the specialist service recommending the treatment is funded by the NHS and has provided NHS funded care for that patient AND • The treatment is for hypertrophic or keloid scars that result from burns, trauma, keloid formation, or surgery and only when one or more of the following clinical criteria are met: a). Scar is functionally disabling b). Scar results in facial disfigurement | Green Specialist Initiation | |
Silk Garment | For treating skin conditions i.e. eczema, atopic dermatitis | Do not prescribe | WY ICS APC November 2022 |
Simeprevir | Hepatitis C (commissioned by NHS England) | Red | |
Simeticone | Oesophageal cancer in palliative care | Specialist Recommendation | WY ICS APC November 2022 |
Simeticone | For all other indications | Do not prescribe | WY ICS APC November 2022 |
Siponimod | Multiple sclerosis (MS) (commissioned by NHS England) | Red | |
Sirolimus | Prophylaxis of organ rejection in transplant patients | Amber | |
Sirolimus (Oral) | For cardiac rhabdomyoma in neonates and paediatrics | Red | WY ICS APC November 2022 |
Sirolimus Topical | For treatment of angiofibroma’s associated with tuberous sclerosis for adults and children (0.1% and 0.5% strengths). Also, for the treatment of venous malformations in adults and children (0.5% strength only). Only for use in line with local formulary/NICE TAs; and where funded/NHSE commissioned – Seek specialist advice | Red | WY ICS APC March 2023 (n) |
Sitagliptin | Type 2 diabetes (T2DM) | Green | |
Sodium benzoate | Urea cycle disorders | Red | |
Sodium bicarbonate capsules | Hyperacidity dyspepsia and symptomatic relief of heartburn and peptic ulceration | Specialist Recommendation | WY ICS APC November 2022 |
Sodium Bicarbonate (Sodium Hydrogen Carbonate) GR capsules (Nephrotrans) | 2nd line as an option after immediate release sodium bicarbonate capsules. For the treatment of metabolic acidosis and for the maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment. | Specialist Initiation | WY ICS APC Jan 2024 |
Sodium chloride 3% medical device | For paediatric cystic fibrosis | Specialist Recommendation | WY ICS APC Nov 2023 |
Sodium chloride 6% + 7% inhalation solution 4ml vials (all strengths) | For patients with retained bronchopulmonary secretions and where usual treatment is not sufficiently effective | Specialist Recommendation | WY ICS APC Nov 2023 |
Sodium clodronate (IV) | Bisphosphonate – osteolytic lesions, hypercalcaemia and bone pain associated with skeletal masses in breast cancer or multiple myeloma | Red | |
Sodium hyaluronate (Cystistat®) | Interstitial cystitis | Red | |
Sodium oxybate | Narcolepsy with cataplexy in children | Red | |
Sodium phenylbutyrate | Urea cycle disorders | Red | |
Sodium zirconium cyclosilicate | For acute management of hyperkalamia as per NICE TA599 | Red | WY ICS APC 24th May 2023 |
Sodium zirconium cyclosilicate | For management of hyperkalaemia in dialysis patients as per NICE TA599 update | Specialist Initiation | WY ICS APC 24th May 2023 |
Sofosbuvir | Hepatitis C (commissioned by NHS England) | Red | |
Sofosbuvir/ledipasvir (Harvoni®) | Hepatitis C (commissioned by NHS England) | Red | |
Sofosbuvir/velpatasvir | Hepatitis C (commissioned by NHS England) | Red | |
Solriamfetol | For treating excessive daytime sleepiness caused by narcolepsy NICE TA758 | Red | WY ICS APC November 2022 |
Somatrogon | For treating growth disturbance in children and young people aged 3 and over. | Specialist Initiation with additional guidance | WY ICS APC January 2024 |
Somatropin for adults | Acquired adult-onset post-surgery growth hormone deficiency *Please note that Omnitrope® is what we commission in adults as growth hormone product of choice* | Amber | |
Somatropin for paediatrics | For the treatment of Growth Hormone Insufficiency in Paediatrics | Green Specialist Initiation SWYAPC | 30th September 2020 (n) |
Sorafenib | Treatment of cancers | Red | |
Sotorasib | For previously treat KRAS G12C mutation-positive advanced non-small cell lung cancer NICE TA781 | Red | WY ICS APC September 2022 |
Sotrovimab | A dual-action nMAB that both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2 | Red | WY ICS APC Chair's action January 2022. |
Spectinomycin | Used as an antibiotic for the treatment of gonorrhoea infections | Red | |
St Mark's solution | For use in the management of short bowel syndrome to maintain an adequate fluid balance and minimise stool output. The unlicensed produce should not be prescribed and should be prepared at home as per the following link. St Mark's solution | Do Not Prescribe | WY ICS APC Nov 2023 |
Stavudine | HIV infection (commissioned by NHS England) | Discontinued NICE guidance - Sept 2020 | |
Stiripentol | Rare forms of epilepsy | Red | |
Streptomycin | Treatment of TB | Red | |
Strimvelis® | Adenosine deaminase deficiency-severe combined immundeficiency | Red | |
Subcutaneous (SC) human normal immunoglobulins | All indications | Red | 4th Sept 2020 |
Subgam® | All indications | Red | |
Sucroferric oxyhydroxide | Control of serum phosphorus levels in dialysis patients | Red | |
Sugammadex | Reversal of neuromuscular blockade induced by rocuronium or vecuronium | Red | |
Sucralfate | All indications | Red | |
Sufentanil | Management of acute moderate to severe pain in adults | Do not Prescribe/Not yet Classified | WY ICS APC Jan 2024 |
Sulcralfate oral (tablets, liquids) | Licensed indications for an unlicensed product - benign gastric ulceration, benign duodenal ulcertions, chronic gastritis, prophylaxis of stress ulceration in child under intensive care and prophylaxis of stress ulceration. | Specialist Recommendation | WY ICS APC November 2022 |
Sulfasalazine | Licensed indication - rheumatoid arthritis (RA). Off-label - other inflammatory arthritides | Amber | |
Sulfasalazine | Paediatric rheumatology | Amber | |
Sunitinib | Treatment of cancers | Red | |
Susoctocog alfa | Haemophilia A | Red | |
Tacrolimus (oral) | Immunosuppressant for transplant patients | Amber | |
Tacrolimus | Post paediatric renal transplant | Amber | |
Tacrolimus (Adoport®) | Treatment of Crohns Disease unresponsive to other immunosuppressants (off-label use) | LTHT | Under review |
Tacrolimus | Nephrotic Syndrome in children | Amber | |
Tacrolimus suppositories | Active proctitis | Red | 22nd January 2020 |
Tacrolimus (topical) | Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids | Green | |
Tacrolimus (Topical) 0.1% ointment and mouthwash made from 1mg capsules | For the treatment of oral lichen planus and similar immune-inflammatory oral mucosal disease (off-licence). Patients should be counselled on how to make up the mouthwash. Prescribers will communicate the dose/indication clearly to the GP practice. | Specialist Recommendation | WY ICS APC March 2023 |
Tadalafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black | |
Tadalafil once daily | Erectile dysfunction | Green | ICS APC September 2021 |
Tadalafil | Pulmonary arterial hypertension | Red | |
Tafamidis | For treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR CM) in adults | Red for existing patients. Do not prescribe for new patients | 8th September 2021 |
Tafasitamab | Indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) in combination with lenalidomide or as monotherapy NICE TA883. | Do Not Prescribe | WY ICS APC Nov 2023 |
Tafluprost | Glaucoma | Green Specialist Initiation | |
Taliglucerase alfa | Gaucher's disease | Red | |
Talimogene laherparepvec | Treatment of cancers | Red | |
Tamsulosin/solifenacin | Indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy. Please note tamsulosin and solifenacin may still be prescribed separately. | Do not prescribe | WY ICS APC Sept 2023 |
Tapentadol modified-release tablets | Chronic non-malignant pain | Green Specialist Initiation | |
Taurine | Cystic fibrosis (CF) management | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
TB drugs | Red when used for TB (except levofloxacin, ofloxacin, co-amoxiclav and clarithromysin) | Red | |
Teduglutide | For treating short bowel syndrome NICE TA804 | Red | ICS APC November 2022 |
Tegafur with uracil | Treatment of cancers | Red | |
Telaprevir | Hepatitis C (commissioned by NHS England) | Red | |
Temozolomide | Treatment of cancers; endocrinology; non-malignant conditions | Red | |
Temsirolimus | Treatment of cancers | Red | |
Tenofovir alafenamide | Hepatitis B (commissioned by NHS England) | Red | |
Tenofovir | HIV infection/hepatits B (commissioned by NHS England) | Red | |
Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine | HIV infection (commissioned by NHS England) | Red | |
Tenofovir disoproxil/cobicistat/elvitegravir/emtricitabine | HIV infection (commissioned by NHS England) | Red | |
Tenofovir/efavirenz/emtricitabine | HIV infection (commissioned by NHS England) | Red | |
Tenofovor/emtricitabine/rilpiverine | HIV infection (commissioned by NHS England) | Red | |
Tepotinib hydrochloride hydrate | Indicated for the treatment of adult patients with advanced non-small cell lung cancer NICE TA789 | Red | ICS APC November 2022 |
Teriflunomide (Aubagio) | Treatment of adult and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) as per NICE TA303. | Red | WY ICS APC 24th May 2023 |
Teriparatide | All indications | Red | |
Testosterone gels | Hypogonadism due to testosterone deficiency in men | Green Specialist Initiation | |
Testosterone transdermal | For menopausal women with low sexual desire if HRT alone is not effective (licensed medicines unlicensed use) | Specialist Recommendation | ICS APC September 2021 (n) |
Tetrahydrobiopterin | Phenylketonuria | Red | |
Tezepelumab | For treating severe asthma. | Red | WY ICS APC July 2023 |
Thalidomide | All indications | Red | |
Thalidomide capsules | For resistant, recurrent major aphthous stomatitis | Red | ICS APC Chair's action 2022. |
Thiotepa | As conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation | Red | 22nd September 2021 (n) |
Thrombomodulin recombinant Human | For treating pulmonary hypertension and pseudoaneurysm | Red | WY ICS APC 24th May 2023 |
Ticagrelor | For preventing atherothrombotic events after myocardial infarction or with acute coronary syndrome. For use as antiplatelet therapy for percutaneous coronary intervention (PCI) | Specialist Initiation | WY ICS APC Nov 2023 (a) |
Ticagrelor 60mg | The recommendation to switch to 60mg can be made in the original eDAN at discharge post MI or via the A&G route i.e. without a patient needing direct contact with the specialist | Specialist Recommendation | WY ICS APC Nov 2023 |
Tick-bourne encephalitis vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Tildrakizumab | Plaque psoriasis in adults | Red | 20th September 2019 (n) |
Timolol/brinzolamide eye erops (Azarga®) | Glaucoma | Green Specialist Initiation | |
Tioguanine | Treatment of cancers | Red | |
Tiopronin | Management of Cystinuria (prophylactic/reducing agent). Unlicensed medicine. | Red | WY ICS APC July 2023. |
Tipranavir | HIV infection | Red | |
Tirbanibulin | For actinic keratosis (Olsen grade 1) of the face or scalp in adults. | Green | WY ICS APC 24th May 2023 |
Tirzepatide Injection 2.5mg & 5mg | For type 2 diabetes in line with NICE TA924 | Green Restricted | WY ICS Jan 2024 |
Tirzepatide with insulin | For type 2 diabetes in line with SmPC | Specialist Recommendation | WY ICS APC Jan 2024 |
Tirzepatide doses above 5mg | For type 2 diabetes in line with NICE TA924 | Specialist Recommendation | WY ICS APC Jan 2024 |
Tirzepatide for all strengths | For weight management | Do not Prescribe | WY ICS APC Jan 2024 |
Tisagenlecleucel | Treatment of cancer (commissioned by NHS England) | Red | |
Tivozanib | Cancer | Red | |
Tixagevimab | For preventing COVID-19 (with cilgavimab) NICE TA900 | Do Not Prescribe | WY ICS APC Nov 2023 |
Tizanidine | Spasticity | Green Specialist Initiation | |
Tizanidine | Cerebral Palsy Spasticity in Children | Green Specialist Initiation See LTHT guidance for information | |
Tobramycin | For corneal ulcers and keratitis under microbiology direction | Red | ICS APC September 2022 |
Tobramycin (Tobi®) nebuliser solution | Cystic fibrosis (CF) management | Amber | |
Tobramycin dry powder inhaler | Suppression of chronic pulmonary infections in cystic fibrosis | Red | |
Tocilizumab | All indications | Red | |
Tofacitinib | Paediatric indications (where adult NICE TA available) | Red | |
Tofacitinib | For ulcerative colitis NICE TA547 | Red | ICS APC November 2022 |
Tofacitinib | For juvenile idiopathic arthritis NICE TA735 (for this indication) | Red | ICS APC April 2022 |
Tofacitinib | With or without methotrexate for moderate to severe active rheumatoid arthritis (RA) in adults according to NICE TA480. Also for active psoriatic arthritis in adults according to NICE TA543 in combination with methotrexate | Red | |
Tofacitinib | For all indications | Red | WY ICS APC Jan 2024 |
Tolvaptan | Hyponatraemia secondary to secretion of inappropriate antidiuretic hormone secretion (SIADH) | Red | |
Topiramate | Paediatric Migraine | Green Specialist Initiation See LTHT guidance for information | |
Topotecan | Cancer chemotherapy | Red | |
Toremifene | Metastatic breast cancer | Green Specialist Initiation | |
Touchcare nano | Type 1 diabetes, pregnancy type 1 and 2 diabetes and other commissioned types of diabetes as described in theWY ICS Commissioning Statement | Red | Chair's Action ICS APC May 2023 |
Trabectedin | Treatment of cancers | Red | |
TraLife® oral spray | Oral hygeine | Red | |
Trametinib | Treatment of cancers | Red | |
Trametinib | For histiocytic disorders | Red | WY ICS APC April 2022 |
Tranexamic Acid Injection (procedure related use) | For controlling latrogenic bleeding during flexible bronchoscopy. The oral form is classified as Green | Red | WY ICS APC Nov 2023 |
Tranexamic Acid Oral | For menorrhagia or local fibrinolysis or hereditary angioedema or epistaxis. The injection is classified as red. | Green | WY ICS APC Nov 2023 |
Trastuzumab deruxtecan | Treating HER2-positive unresectable or metastatic breast cancer | Red | 28th July 2021 (n) |
Trastuzumab | Treatment of cancers | Red | |
Trastuzumab deruxtecan | For HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies NICE TA704 | Red | ICS APC April 2022 |
Trastuzumab emtansine | Treatment of cancers | Red | |
Travel vaccines | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Travoprost/timolol (Duotrav®) | Rasied intra-ocular pressure | Green Specialist Initiation | |
Trazodone hydrochloride | An antidepressant used for depression and anxiety | Green | WY ICS APC Jan 2024 |
Treosulfan | Treatment of cancers | Red | |
Treprostinil sodium | For pulmonary arterial hypertension. NHSE do not routinely commission for new patients | Do not prescribe | WY ICS APC 24th May 2023 |
Tretinoin (oral) | Antineoplastic; induction of remission in acute promyelocytic leukaemia | Red | |
Triamcinolone acetonide 40mg (Kenalog) | For treatment of Hayfever (ULM) | Do not prescribe | ICS APC November 2022 |
Triamcinolone hexacetonide (Lederspan®) | Unlicensed - depot steroid injection for use in children | Red | |
Trientine | Wilson's disease | Red | |
Trifluridine/tipiracil | Treatment of cancers | Red | |
Trimipramine | For all indications | Black for new patients NHSE items that should not be routinely prescribed in Primary Care | |
Triptorelin | Endometriosis or uterine fibroids | Amber - see GnRH analogues | |
Triptorelin | Precocious puberty | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. | |
Triptorelin | Management of prostate cancer | Amber - see GnRH analogues | |
Trospium MR | Urinary incontinence | Green | |
Trospium XL | Urinary incontinence | Green | |
Trusses | Surgical appliance for hernia patients | Do not prescribe | ICS APC November 2022 |
Tryptophan | Severe disabling depression. Unlicensed product - named patient use only | Red | |
Tucatinib | Use in combination with trastuzumab and capecitabine for the treatment of adults with HER2-positive locally advanced or metastatic breast cancer NICE TA786 | Red | ICS APC November 2022 |
Turotocog alfa | Haemophilia A | Red | |
Ulipristal 5mg | 1. Pre-operative management of uterine fibroids. Alternative treatment to hysterectomy, myomectomy, uterine embolization or GnRH agonists in perimenopausal patients with moderate to severe symptoms caused by fibroids. Also considered in younger patients with high surgical/anaesthetic risks. 2. Intermittent treatment of moderate to severe symptoms of uterine fibroids | Suspended | MHRA Safety Alert March 2020 |
Ultibro Breezhaler® | Chronic obstructive pulmonary disease (COPD) | Green | |
Uridine Triacetate | Treatment of Toxixity with 5-FU and capecitabine | Red | 4th Sept 2020 |
Upadacitinib | For moderate rheumatoid arthritis NICE TA744 | Red | ICS APC April 2022 |
Upadactinib | For treating active psoriatic arthritis after inadequate response to DMARDS NICE TA768 | Red | WY ICS APC 22nd June 2022 |
Upadacitinib M/R tablets | Licensed for the treatment of moderate to severe atopic dermatitis | Red | ICS APC March 2022 (n) |
Upadacitinib tablets | For the treatment of severe rheumatoid arthritis (RA) NICE TA665, TA744 & T768 | Red | ICS APC September 2022 |
Urofollitropin | IVF treatment | Red | |
Uroshield | For preventing catheter - associated urinary tract infections | Do not prescribe/not yet classified | ICS APC November 2022 |
Ustekinumab | All indications | Red | |
Valaciclovir | For the treatment of Herpes Simplex Virus (HSV) Encephalitis in Paediatrics | Green Specialist Initiation See LTHT guidance for information | |
Valganciclovir | All indications | Red | |
Valproate | All indications | Green Specialist Initiation | |
Vandetanib | Thyroid cancer | Red | |
Vardenafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black | |
Vedolizumab | All indications | Red | WY ICS APC Jan 2024 |
Velaglucerase alfa | Gaucher's disease | Red | |
Vemurafenib | Melanoma | Red | |
Venetoclax | Cancer | Red | |
Venetoclax | In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy | Red | |
Venetoclax with azactidine | For untreated actute myeloid leukaemia in adults with intensive chemotherapy is unsuitable NICE TA765 | Red | ICS APC April 2022 |
Venlafaxine (at doses over 300mg daily) | Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia | Green Specialist Initiation | Updated 17.02.2020 |
Verteporfin | Age related macular degeneration | Red | |
Vibropulse | Cellulitis, venous leg ulcers and lower limb oedema | Black | 22nd January 2020 (n) |
Viekirax® | Hepatitis C (commissioned by NHS England) | Red | |
Vigam® | All indications | Red | |
Vildagliptin | Type 2 diabetes (T2DM) | Green | |
Vildagliptin with metformin | Type 2 diabetes (T2DM) | Green | |
Vinblastine | Treatment of cancers | Red | |
Vincristine | Treatment of cancers | Red | |
Vinorelbine | Treatment of cancers | Red | |
Vismodegib | Treatment of cancers | Red | |
Vitamin A | Retinosa pigmentosa | Red | |
Vivaglobin® | All indications | Red | |
Voclosporin | For treating lupus nephritis (with immunosuppressives). | Red | WY ICS APC July 2023. |
Volanesorsen | Familial chylomicronemia syndrome (commissioned by NHS England) | Red | |
Von Willebrand factor, recombinant | Von Willebrand deficiency | Red | |
Vonicog alfa injection | Von Willebrand deficiency (commissioned by NHS England) | Red | ICS APC March 2022 (n) |
Voretigene neparvovec | Inherited retinal dystrophies (commissioned by NHS England) | Red | |
Voriconazole | Fungal infections. Chronic pulmonary aspergillosis | Red | |
Voriconazole eye drops | Candida keratitis | Red | 29th July 2020 (n) |
Vortioxetine | For treating major depressive episodes | Specialist Initiation | WY ICS APC Jan 2024 |
Voxelotor | Sickle cell disease (commissioned by NHS England) | Red | |
Vutrisiran | For treating hereditary transthyretin-related amyloidosis as per NICE TA868 | Red | WY ICS APC 24th May 2023 |
Yellow fever vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care | |
Zalepion | A hypnotic Z-drug for insomnia (short-term use) 4 weeks or less | Green | WY ICS APC Jan 2024 |
Zanubrutinib | For relapsed or refractory Waldenstrom's Macroglobulinemia | Red | ICS APC April 2022 |
Zanubrutinib | For treating chronic lymphocytic leukaemia | Red | WY ICS APC Jan 2024 |
Ziconotide | Non-opioid analgesic administered by intrathecal infusion | Red | |
Zidovudine | HIV infection (commissioned by NHS England) | Red | |
Zidovudine/lamivudine | HIV infection (commissioned by NHS England) | Red | |
Zidovudine/lamivudine/abacavir | HIV infection (commissioned by NHS England) | Red | |
Zoledronic acid | Prevention of skeletal related events (pathological, spinal compression, radiation/surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tomour-induced hypercalcaemia | Red | |
Zolpidem tartrate | A hypnotic Z-drug for insomnia (short-term use) 4 weeks or less | Green | WY ICS APC Jan 2024 |
Zopicione | A hypnotic Z-drug for insomnia (short-term use) 4 weeks or less | Green | WY ICS APC Jan 2024 |